A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.
Inorganic or organic compounds that contain the basic structure RB(OH)2.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
Specialized forms of antibody-producing B-LYMPHOCYTES. They synthesize and secrete immunoglobulin. They are found only in lymphoid organs and at sites of immune responses and normally do not circulate in the blood or lymph. (Rosen et al., Dictionary of Immunology, 1989, p169 & Abbas et al., Cellular and Molecular Immunology, 2d ed, p20)
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.
Conditions characterized by the presence of M protein (Monoclonal protein) in serum or urine without clinical manifestations of plasma cell dyscrasia.
A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.
Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.
An anti-inflammatory 9-fluoro-glucocorticoid.
Transplantation of an individual's own tissue from one site to another site.
A syndecan that interacts with EXTRACELLULAR MATRIX PROTEINS and plays a role CELL PROLIFERATION and CELL MIGRATION.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A cell line derived from cultured tumor cells.
An abnormal protein with unusual thermosolubility characteristics that is found in the urine of patients with MULTIPLE MYELOMA.
Abnormal immunoglobulins synthesized by atypical cells of the MONONUCLEAR PHAGOCYTE SYSTEM. Paraproteins containing only light chains lead to Bence Jones paraproteinemia, while the presence of only atypical heavy chains leads to heavy chain disease. Most of the paraproteins show themselves as an M-component (monoclonal gammopathy) in electrophoresis. Diclonal and polyclonal paraproteins are much less frequently encountered.
Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Compounds that inhibit the function or proteolytic action of the PROTEASOME.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Dissolution of bone that particularly involves the removal or loss of calcium.
Diseases of BONES.
A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS.
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
A specific pair of GROUP D CHROMOSOMES of the human chromosome classification.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
One of the types of light chains of the immunoglobulins with a molecular weight of approximately 22 kDa.
Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A family of transmembrane glycoproteins that contain a short cytoplasmic domain, a single-span transmembrane domain, and an extracellular domain with heparin sulfate and CHONDROITIN SULFATE chains. Syndecans interact with a variety of heparin-binding INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS and may play a role in modulating cellular signaling during EMBRYONIC DEVELOPMENT, tumorigenesis, and angiogenesis.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Treatment designed to help prevent a relapse of a disease following the successful primary treatments (INDUCTION CHEMOTHERAPY and CONSOLIDATION CHEMOTHERAPY) with a long-term low-dose drug therapy.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
One of the types of light chain subunits of the immunoglobulins with a molecular weight of approximately 22 kDa.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Therapeutic act or process that initiates a response to a complete or partial remission level.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The return of a sign, symptom, or disease after a remission.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.
A specific pair of GROUP D CHROMOSOMES of the human chromosome classification.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
An excess of GAMMA-GLOBULINS in the serum due to chronic infections or PARAPROTEINEMIAS.
An 11-kDa protein associated with the outer membrane of many cells including lymphocytes. It is the small subunit of the MHC class I molecule. Association with beta 2-microglobulin is generally required for the transport of class I heavy chains from the endoplasmic reticulum to the cell surface. Beta 2-microglobulin is present in small amounts in serum, csf, and urine of normal people, and to a much greater degree in the urine and plasma of patients with tubular proteinemia, renal failure, or kidney transplants.
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Removal of bone marrow and evaluation of its histologic picture.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
Cell surface receptors that are specific for INTERLEUKIN-6. They are present on T-LYMPHOCYTES, mitogen-activated B-LYMPHOCYTES, and peripheral MONOCYTES. The receptors are heterodimers of the INTERLEUKIN-6 RECEPTOR ALPHA SUBUNIT and the CYTOKINE RECEPTOR GP130.
A specific pair of GROUP B CHROMOSOMES of the human chromosome classification.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
A fibroblast growth factor receptor that regulates CHONDROCYTE growth and CELL DIFFERENTIATION. Mutations in the gene for fibroblast growth factor receptor 3 have been associated with ACHONDROPLASIA; THANATOPHORIC DYSPLASIA and NEOPLASTIC CELL TRANSFORMATION.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
An immunoglobulin which accounts for less than 1% of plasma immunoglobulin. It is found on the membrane of many circulating B LYMPHOCYTES.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
The action of a drug in promoting or enhancing the effectiveness of another drug.
Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.
A large multinuclear cell associated with the BONE RESORPTION. An odontoclast, also called cementoclast, is cytomorphologically the same as an osteoclast and is involved in CEMENTUM resorption.
Antibodies produced by a single clone of cells.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
A general term for various neoplastic diseases of the lymphoid tissue.
Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Death of a bone or part of a bone, either atraumatic or posttraumatic.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Elements of limited time intervals, contributing to particular results or situations.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Binary compounds of oxygen containing the anion O(2-). The anion combines with metals to form alkaline oxides and non-metals to form acidic oxides.

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. (1/5264)

Interleukin 6 (IL-6) is the major survival factor for myeloma tumor cells and induces signaling through the STAT proteins. We report that one STAT family member, Stat3, is constitutively activated in bone marrow mononuclear cells from patients with multiple myeloma and in the IL-6-dependent human myeloma cell line U266. Moreover, U266 cells are inherently resistant to Fas-mediated apoptosis and express high levels of the antiapoptotic protein Bcl-xL. Blocking IL-6 receptor signaling from Janus kinases to the Stat3 protein inhibits Bcl-xL expression and induces apoptosis, demonstrating that Stat3 signaling is essential for the survival of myeloma tumor cells. These findings provide evidence that constitutively activated Stat3 signaling contributes to the pathogenesis of multiple myeloma by preventing apoptosis.  (+info)

Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. (2/5264)

Oncogenes are often dysregulated in B cell tumors as a result of a reciprocal translocation involving an immunoglobulin locus. The translocations are caused by errors in two developmentally regulated DNA recombination processes: V(D)J and IgH switch recombination. Both processes share the property of joining discontinuous sequences from one chromosome and releasing intervening sequences as circles that are lost from progeny cells. Here we show that these intervening sequences may instead insert in the genome and that during productive IgH mu-epsilon switch recombination in U266 myeloma tumor cells, a portion of the excised IgH switch intervening sequences containing the 3' alpha-1 enhancer has inserted on chromosome 11q13, resulting in overexpression of the adjacent cyclin D1 oncogene.  (+info)

Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. (3/5264)

Immunohistochemical, cytochemical and ultrastructural data showing vivid angiogenesis and numerous mast cells (MCs) in the bone marrow of 24 patients with active multiple myeloma (MM) compared with 34 patients with non-active MM and 22 patients with monoclonal gammopathy of undetermined significance (MGUS) led us to hypothesize that angiogenesis parallels progression of MM, and that MCs participate in its induction via angiogenic factors in their secretory granules.  (+info)

Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. (4/5264)

Whether Kaposi's sarcoma herpesvirus (KSHV) is associated with multiple myeloma (MM) remains controversial. We assayed for KSHV DNA sequences in long-term bone marrow stromal cells (BMSCs) from 26 patients with MM and 4 normal donors. Polymerase chain reaction (PCR) using primers which amplify a KSHV gene sequence to yield a 233-bp fragment (KS330233 within open reading frame 26) was negative in all cases. Aliquots of these PCR products were used as templates in subsequent nested PCR, with primers that amplify a 186-bp product internal to KS330233. BMSCs from 24 of 26 (92%) patients with MM and 1 of 4 normal donors were KSHV PCR+. DNA sequence analyses showed interpatient specific mutations (2 to 3 bp). Both Southern blot and sequence analyses confirmed the specificity of PCR results. The presence of the KSHV gene sequences was further confirmed by amplifying T 1.1 (open reading frame [ORF] K7) and viral cyclin D (ORF 72), two other domains within the KSHV genome. Immunohistochemical studies of KSHV PCR+ MM BMSCs demonstrate expression of dendritic cell (DC) lineage markers (CD68, CD83, and fascin). Serological studies for the presence of KSHV lytic or latent antibodies were performed using sera from 53 MM patients, 12 normal donors, and 5 human immunodeficiency virus (HIV)/KSHV+ patients. No lytic or latent antibodies were present in sera from either MM patients or normal donors. Taken together, these findings show that KSHV DNA sequences are detectable in BMSCs from the majority of MM patients, but that serologic responses to KSHV are not present. Ongoing studies are defining whether the lack of antibody response is caused by the absence of ongoing infection, the presence of a novel viral strain associated with MM, or underlying immunodeficiency in these patients.  (+info)

Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. (5/5264)

Multiple myeloma (MM) cells express idiotypic proteins and other tumor-associated antigens which make them ideal targets for novel immunotherapeutic approaches. However, recent reports show the presence of Kaposi's sarcoma herpesvirus (KSHV) gene sequences in bone marrow dendritic cells (BMDCs) in MM, raising concerns regarding their antigen-presenting cell (APC) function. In the present study, we sought to identify the ideal source of DCs from MM patients for use in vaccination approaches. We compared the relative frequency, phenotype, and function of BMDCs or peripheral blood dendritic cells (PBDCs) from MM patients versus normal donors. DCs were derived by culture of mononuclear cells in the presence of granulocyte-macrophage colony-stimulating factor and interleukin-4. The yield as well as the pattern and intensity of Ag (HLA-DR, CD40, CD54, CD80, and CD86) expression were equivalent on DCs from BM or PB of MM patients versus normal donors. Comparison of PBDCs versus BMDCs showed higher surface expression of HLA-DR (P =.01), CD86 (P =. 0003), and CD14 (P =.04) on PBDCs. APC function, assessed using an allogeneic mixed lymphocyte reaction (MLR), demonstrated equivalent T-cell proliferation triggered by MM versus normal DCs. Moreover, no differences in APC function were noted in BMDCs compared with PBDCs. Polymerase chain reaction (PCR) analysis of genomic DNA from both MM patient and normal donor DCs for the 233-bp KSHV gene sequence (KS330233) was negative, but nested PCR to yield a final product of 186 bp internal to KS330233 was positive in 16 of 18 (88.8%) MM BMDCs, 3 of 8 (37.5%) normal BMDCs, 1 of 5 (20%) MM PBDCs, and 2 of 6 (33.3%) normal donor PBDCs. Sequencing of 4 MM patient PCR products showed 96% to 98% homology to the published KSHV gene sequence, with patient specific mutations ruling out PCR artifacts or contamination. In addition, KHSV-specific viral cyclin D (open reading frame [ORF] 72) was amplified in 2 of 5 MM BMDCs, with sequencing of the ORF 72 amplicon revealing 91% and 92% homology to the KSHV viral cyclin D sequence. These sequences again demonstrated patient specific mutations, ruling out contamination. Therefore, our studies show that PB appears to be the preferred source of DCs for use in vaccination strategies due to the ready accessibility and phenotypic profile of PBDCs, as well as the comparable APC function and lower detection rate of KSHV gene sequences compared with BMDCs. Whether active KSHV infection is present and important in the pathophysiology of MM remains unclear; however, our study shows that MMDCs remain functional despite the detection of KSHV gene sequences.  (+info)

Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. (6/5264)

Integrin-mediated adhesion influences cell survival and may prevent programmed cell death. Little is known about how drug-sensitive tumor cell lines survive initial exposures to cytotoxic drugs and eventually select for drug-resistant populations. Factors that allow for cell survival following acute cytotoxic drug exposure may differ from drug resistance mechanisms selected for by chronic drug exposure. We show here that drug-sensitive 8226 human myeloma cells, demonstrated to express both VLA-4 (alpha4beta1) and VLA-5 (alpha5beta1) integrin fibronectin (FN) receptors, are relatively resistant to the apoptotic effects of doxorubicin and melphalan when pre-adhered to FN and compared with cells grown in suspension. This cell adhesion mediated drug resistance, or CAM-DR, was not due to reduced drug accumulation or upregulation of anti-apoptotic Bcl-2 family members. As determined by flow cytometry, myeloma cell lines selected for drug resistance, with either doxorubicin or melphalan, overexpress VLA-4. Functional assays revealed a significant increase in alpha4-mediated cell adhesion in both drug-resistant variants compared with the drug-sensitive parent line. When removed from selection pressure, drug-resistant cell lines reverted to a drug sensitive and alpha4-low phenotype. Whether VLA-4-mediated FN adhesion offers a survival advantage over VLA-5-mediated adhesion remains to be determined. In conclusion, we have demonstrated that FN-mediated adhesion confers a survival advantage for myeloma cells acutely exposed to cytotoxic drugs by inhibiting drug-induced apoptosis. This finding may explain how some cells survive initial drug exposure and eventually express classical mechanisms of drug resistance such as MDR1 overexpression.  (+info)

Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. (7/5264)

The receptor for hyaluronan (HA)-mediated motility (RHAMM) controls motility by malignant cells in myeloma and is abnormally expressed on the surface of most malignant B and plasma cells in blood or bone marrow (BM) of patients with multiple myeloma (MM). RHAMM cDNA was cloned and sequenced from the malignant B and plasma cells comprising the myeloma B lineage hierarchy. Three distinct RHAMM gene products, RHAMMFL, RHAMM-48, and RHAMM-147, were cloned from MM B and plasma cells. RHAMMFL was 99% homologous to the published sequence of RHAMM. RHAMM-48 and RHAMM-147 variants align with RHAMMFL, but are characterized by sequence deletions of 48 bp (16 amino acids [aa]) and 147 bp (49 aa), respectively. The relative frequency of these RHAMM transcripts in MM plasma cells was determined by cloning of reverse-transcriptase polymerase chain reaction (RT-PCR) products amplified from MM plasma cells. Of 115 randomly picked clones, 49% were RHAMMFL, 47% were RHAMM-48, and 4% were RHAMM-147. All of the detected RHAMM variants contain exon 4, which is alternatively spliced in murine RHAMM, and had only a single copy of the exon 8 repeat sequence detected in murine RHAMM. RT-PCR analysis of sorted blood or BM cells from 22 MM patients showed that overexpression of RHAMM variants is characteristic of MM B cells and BM plasma cells in all patients tested. RHAMM also appeared to be overexpressed in B lymphoma and B-chronic lymphocytic leukemia (CLL) cells. In B cells from normal donors, RHAMMFL was only weakly detectable in resting B cells from five of eight normal donors or in chronically activated B cells from three patients with Crohn's disease. RHAMM-48 was detectable in B cells from one of eight normal donors, but was undetectable in B cells of three donors with Crohn's disease. RHAMM-147 was undetectable in normal and Crohn's disease B cells. In situ RT-PCR was used to determine the number of individual cells with aggregate RHAMM transcripts. For six patients, 29% of BM plasma cells and 12% of MM B cells had detectable RHAMM transcripts, while for five normal donors, only 1. 2% of B cells expressed RHAMM transcripts. This work suggests that RHAMMFL, RHAMM-48, and RHAMM-147 splice variants are overexpressed in MM and other B lymphocyte malignancies relative to resting or in vivo-activated B cells, raising the possibility that RHAMM and its variants may contribute to the malignant process in B-cell malignancies such as lymphoma, CLL, and MM.  (+info)

Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. (8/5264)

We determined the effects of the potent bisphosphonate ibandronate in a murine model of human myeloma bone disease. In this model, bone lesions typical of the human disease develop in mice following inoculation of myeloma cells via the tail vein. Treatment with ibandronate (4 micrograms per mouse per day) significantly reduced the occurrence of osteolytic bone lesions in myeloma-bearing mice. However, ibandronate did not prevent the mice from developing hindlimb paralysis and did not produce a detectable effect on survival. There was no significant effect of ibandronate on total myeloma cell burden, as assessed by morphometric measurements of myeloma cells in the bone marrow, liver, and spleen, or by measurement of serum IgG2b levels. These results support clinical findings that bisphosphonates may be useful for the treatment of myeloma-associated bone destruction, but suggest that other therapies are also required to reduce tumor growth.  (+info)

TY - JOUR. T1 - International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease. AU - Terpos, Evangelos. AU - Morgan, Gareth. AU - Dimopoulos, Meletios A.. AU - Drake, Matthew T.. AU - Lentzsch, Suzanne. AU - Raje, Noopur. AU - Sezer, Orhan. AU - García-Sanz, Ramón. AU - Shimizu, Kazuyuki. AU - Turesson, Ingemar. AU - Reiman, Tony. AU - Jurczyszyn, Artur. AU - Merlini, Giampaolo. AU - Spencer, Andrew. AU - Leleu, Xavier. AU - Cavo, Michele. AU - Munshi, Nikhil. AU - Rajkumar, S. Vincent. AU - Durie, Brian G.M.. AU - Roodman, G. David. N1 - Publisher Copyright: © 2013 by American Society of Clinical Oncology. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.. PY - 2013/6/20. Y1 - 2013/6/20. N2 - Purpose The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease. Methodology An interdisciplinary panel of clinical experts on MM and myeloma ...
25.1. Introduction. 25.2. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. 25.2.1. Definition of multiple myeloma. 25.2.2. Definition of smouldering multiple myeloma. 25.2.3. Definition of monoclonal gammopathy of undetermined significance. 25.3. International Myeloma Working Group guidelines. 25.3.1. Guidelines for serum free light chain analysis in multiple myeloma and related disorders (2009). 25.3.2. Guidelines for monoclonal gammopathy of undetermined significance and smouldering multiple myeloma (2010). 25.3.3. Guidelines for standard investigative work-up of patients with suspected multiple myeloma (2011). 25.3.4. Guidelines for risk stratification in multiple myeloma (2011). 25.3.5. Consensus criteria for response and minimal residual disease assessment in multiple myeloma (2016). 25.3.6. Recommendations for global myeloma care (2013). 25.3.7. Recommendations for the diagnosis and management of myeloma-related renal impairment (2016). 25.4. ...
The latest market report published by Credence Research, Inc. Global Multiple Myeloma Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017 - 2025, the Multiple Myeloma Treatment market was valued at USD 8,398.3 Mn in 2016, and is expected to reach USD 21,221.8 Mn by 2025, expanding at a CAGR of 11.0% from 2017 to 2025.. Browse the full report Multiple Myeloma Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017 - 2025 at http://www.credenceresearch.com/report/multiple-myeloma-treatment-market. Market Insights. Multiple myeloma treatment options have developed significantly over the last decade. Novel multiple myeloma treatments have provided efficient survival rates among myeloma patients. It has been also observed that the upcoming drug pipeline of multiple myeloma is promising, biological drugs and stem cell based therapies are expected to drive the market in the near future. The key players operating in this industry ...
25.1. Introduction. 25.2. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. 25.2.1. Definition of multiple myeloma. 25.2.2. Definition of smouldering multiple myeloma. 25.2.3. Definition of monoclonal gammopathy of undetermined significance. 25.3. International Myeloma Working Group guidelines. 25.3.1. Guidelines for serum free light chain analysis in multiple myeloma and related disorders (2009). 25.3.2. Guidelines for monoclonal gammopathy of undetermined significance and smouldering multiple myeloma (2010). 25.3.3. Guidelines for standard investigative work-up of patients with suspected multiple myeloma (2011). 25.3.4. Guidelines for risk stratification in multiple myeloma (2011). 25.3.5. Consensus criteria for response and minimal residual disease assessment in multiple myeloma (2016). 25.3.6. Recommendations for global myeloma care (2013). 25.3.7. Recommendations for the diagnosis and management of myeloma-related renal impairment (2016). 25.4. ...
To investigate the patterns of genetic lesions in a panel of 23 human multiple myeloma cell lines (HMCLs), we made a genomic integrative analysis involving FISH, and both gene expression and genome-wide profiling approaches. The expression profiles of the genes targeted by the main IGH translocations showed that the WHSC1/MMSET gene involved in t(4;14)(p16;q32) was expressed at different levels in all of the HMCLs, and that the expression of the MAF gene was not restricted to the HMCLs carrying t(14;16)(q32;q23). Supervised analyses identified a limited number of genes specifically associated with t(4;14) and involved in different biological processes. The signature related to MAF/MAFB expression included the known MAF target genes CCND2 and ITGB7, as well as genes controlling cell shape and cell adhesion. Genome-wide DNA profiling allowed the identification of a gain on chromosome arm 1q in 88% of the analyzed cell lines, together with recurrent gains on 8q, 18q, 7q, and 20q; the most frequent ...
43 NCCN Guidelines for Patients ® : Multiple Myeloma, 2018 4 Treatment guide Active (symptomatic) multiple myeloma Active (symptomatic) multiple myeloma Guide 5 shows the primary treatment options for multiple myeloma that is causing symptoms and follow-up tests. Myeloma that is causing symptoms is called active myeloma or symptomatic myeloma. Primary treatment is the first treatment given to try to rid your body of cancer. Primary treatment for active myeloma includes systemic therapies. Systemic therapy travels in your body to treat more than one area of cancer. This type of treatment includes chemotherapy, targeted therapy, and steroids. These drugs may be given alone or in combination. Follow-up tests are usually done after 1 to 2 cycles of treatment to see whether or not the treatment is working or if the disease is progressing (getting worse). Treatment for active myeloma may or may not include a stem cell transplant. A stem cell transplant is not a good treatment option for everyone. ...
TY - JOUR. T1 - Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. AU - Nguyen, Aaron N.. AU - Stebbins, Elizabeth G.. AU - Henson, Margaret. AU - OYoung, Gilbert. AU - Choi, Sun J.. AU - Quon, Diana. AU - Damm, Debby. AU - Reddy, Mamatha. AU - Ma, Jing Y.. AU - Haghnazari, Edwin. AU - Kapoun, Ann M.. AU - Medicherla, Satyanarayana. AU - Protter, Andy. AU - Schreiner, George F.. AU - Kurihara, Noriyoshi. AU - Anderson, Judy. AU - Roodman, G. David. AU - Navas, Tony A.. AU - Higgins, Linda S.. PY - 2006/6/10. Y1 - 2006/6/10. N2 - The multiple myeloma (MM) bone marrow (BM) microenvironment plays a critical role in supporting tumor growth and survival as well as in promoting formation of osteolytic lesions. Recent results suggest that the p38 mitogen-activated protein kinase (MAPK) is an important factor in maintaining this activated environment. In this report, we demonstrate that the p38α ...
The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi. The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival compared to Velcade (Bortezomib), but also overall improved overall survival, making it a clinically meaningful advance in the treatment of relapsed or refractory multiple myeloma. Patients with relapsed or refractory multiple myeloma treated with Kyprolis® and dexamethasone lived 7.6 months longer than those treated with Velcade® and dexamethasone.1. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of the bodys immune system. In the U.S., approximately 70,000 people are living with multiple myeloma and approximately 24,000 new individuals are diagnosed annually. Patients with multiple myeloma have increased numbers of abnormal plasma cells that may produce increased quantities of dysfunctional antibodies detectable in the blood and/or ...
PubMed journal article: Plasma cells in peripheral blood stem cell harvests from patients with multiple myeloma are predominantly polyclonal. Download Prime PubMed App to iPhone, iPad, or Android
References. 1. Centre for Evidence Based Medicine [Internet]. Oxford: University of Oxford; 2011. [cited 2012 Nov 21]. Available from: http:// www.cebm.net. [ Links ] 2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-60. Comment in: N Engl J Med. 2011;364(24):2364; author reply 2364. [ Links ] 3. Hungria VT, Maiolino A, Martinez G, Colleoni GW, Coelho EO, Rocha L, Nunes R, Bittencourt R, Oliveira LC, Faria RM, Pasquini R, Magalhães SM, Souza CA, Pinto Neto JV, Barreto L, Andrade E, Portella M do S, Bolejack V, Durie BG; International Myeloma Working Group Latin America. Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma. Haematologica 2008;93(5):791-2. [ Links ] 4. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment ...
TY - JOUR. T1 - Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo. AU - Opperman, Khatora S.. AU - Vandyke, Kate. AU - Clark, Kimberley C.. AU - Coulter, Elizabeth A.. AU - Hewett, Duncan R.. AU - Mrozik, Krzysztof M.. AU - Schwarz, Nisha. AU - Evdokiou, Andreas. AU - Croucher, Peter I.. AU - Psaltis, Peter. AU - Noll, Jacqueline E.. AU - Zannettino, Andrew. PY - 2019/8/1. Y1 - 2019/8/1. N2 - Multiple myeloma is a fatal plasma cell malignancy that is reliant on the bone marrow microenvironment. The bone marrow is comprised of numerous cells of mesenchymal and hemopoietic origin. Of these, macrophages have been implicated to play a role in myeloma disease progression, angiogenesis, and drug resistance; however, the role of macrophages in myeloma disease establishment remains unknown. In this study, the antimyeloma efficacy of clodronate-liposome treatment, which globally and transiently depletes macrophages, was evaluated in the ...
Multiple myeloma is a haematological malignancy characterized by the clonal proliferation of plasma cells. It has been proposed that targeting cancer cell metabolism would provide a new selective anticancer therapeutic strategy. In this work, we tested the hypothesis that inhibition of β-oxidation and de novo fatty acid synthesis would reduce cell proliferation in human myeloma cells. We evaluated the effect of etomoxir and orlistat on fatty acid metabolism, glucose metabolism, cell cycle distribution, proliferation, cell death and expression of G1/S phase regulatory proteins in myeloma cells. Etomoxir and orlistat inhibited β-oxidation and de novo fatty acid synthesis respectively in myeloma cells, without altering significantly glucose metabolism. These effects were associated with reduced cell viability and cell cycle arrest in G0/G1. Specifically, etomoxir and orlistat reduced by 40-70% myeloma cells proliferation. The combination of etomoxir and orlistat resulted in an additive inhibitory effect
Multiple myeloma is a plasma cell malignancy characterized by complex heterogeneous cytogenetic abnormalities. The bone marrow microenvironment promotes multiple myeloma cell growth and resistance to conventional therapies. Although multiple myeloma remains incurable, novel targeted agents, used alo …
Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The Multiple Myeloma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029 report has been added to ResearchAndMarkets.coms offering. This report offers strategic insights into the overall multiple myeloma treatment market along with the market size and estimates for the duration 2019 to 2029. The said research study cover in-depth analysis of multiple myeloma market segments based on type and different geographies further segmented by countries. According to myeloma UK, in myeloma, plasma cells become abnormal, multiply uncontrollably and release only one type of antibody known as paraprotein, which has no useful function. It is often through the measurement of this paraprotein that myeloma is diagnosed and monitored.For the purpose of this study, the global multiple myeloma treatment market is segmented on the basis of type into Drug Therapy, Stem cell
Many clinical studies for the treatment of multiple myeloma have been conducted in Korea, but none of them have evaluated the improvement in the quality of life in patients with multiple myeloma. Most study variables used to evaluate the quality of life of patients with multiple myeloma are subjective and limited. This study will observe the degree of change in the quality of life in patients with multiple myeloma before and after bortezomib administration by using EORTC-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30) and EQ-5D (EuroQol-5 Dimensions), validated research instruments used to measure the quality of life in cancer patients and consequently will provide fundamental data regarding the quality of life in patients with multiple myeloma.. Observational Study - No investigational drug ...
Celgene Corp. (CELG) announced Friday that the U.S. Food and Drug Administration or FDA has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Background: Elderly patients with multiple myeloma are a challenging population to treat, and there is a need for effective treatment options. Carfilzomib, a selective proteasome inhibitor, is approved in the United States and other countries for the treatment of relapsed or refractory multiple myeloma (RRMM). A subgroup analysis of interim results from the randomized, phase 3 ENDEAVOR study showed that carfilzomib (56 mg/m2) and dexamethasone (Kd56) resulted in longer median progression-free survival (PFS) and higher overall response rates (ORRs) than bortezomib and dexamethasone (Vd) in patients with RRMM, regardless of age (Table; Ludwig et al, Leuk Lymphoma. 2017;58:2501-2504). Mature overall survival (OS) data has recently been reported from ENDEAVOR and demonstrated that Kd56 resulted in statistically and clinically significant improvement in OS compared with Vd in the intention-to-treat (ITT) population (median, 47.6 months vs 40.0 months; hazard ratio [HR], 0.791; 95% confidence interval ...
I have often said , and everyone is probably tired of hearing that a multiple myeloma qualified professional and a well-informed patient can extend your life expectancy. If you listen to Paula multiple myeloma life expectancy, has followed this formula to the letter. He had a first opinion , then a second opinion, and then a third opinion. He contacted the International Monetary Fund (International Myeloma Foundation ) multiple myeloma life expectancy, became a member of the group, and a leader of the group. He chose a great doctor and a treatment of myeloma. His doctor was none other than David S. Siegel, MD , Ph.D., director of the Division of Multiple Myeloma at John There Cancer Center, Hackensack University Medical Center. Before that , he spent years in the center MSN and worked hand in hand with Dr. Bart Brogue . In 1999 , MSN was and is considered one of the best centers in the world myeloma . So Paula has chosen , and he needed it multiple myeloma life expectancy. He discovered that he ...
Data from two phase I/II clinical trials evaluating ixazomib (Ninlaro) in patients with newly diagnosed multiple myeloma was presented at the 2017 European Hematology Association (EHA) Annual Meeting (Abstracts S408, S780). Both studies evaluated ixazomib plus lenalidomide (Revlimid) and dexamethasone in newly diagnosed patients with multiple myeloma who did not undergo stem cell transplant, followed by maintenance with single-agent ixazomib. Ixazomib is currently not approved for the treatment of newly diagnosed multiple myeloma or in the maintenance setting.. Despite recent progress, multiple myeloma remains a rare, devastating, and incurable hematologic cancer.… These phase I/II data demonstrate the potential use of ixazomib in combination with lenalidomide/dexamethasone in newly diagnosed multiple myeloma and as a single-agent maintenance therapy, which resulted in patients achieving deepening responses with continual use of the treatment. Ixazomibs efficacy and safety profile-coupled ...
TY - JOUR. T1 - A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. AU - Noonan, Kimberly. AU - Marchionni, Luigi. AU - Anderson, Judy. AU - Pardoll, Drew. AU - Roodman, G. David. AU - Borrello, Ivan. PY - 2010/11/4. Y1 - 2010/11/4. N2 - Osteoclast (OC)-mediated lytic bone disease remains a cause of major morbidity in multiple myeloma. Here we demonstrate the critical role of interleukin-17-producing marrow infiltrating lymphocytes (MILs) in OC activation and development of bone lesions in myeloma patients. Unlike MILs from normal bone marrow, myeloma MILs possess few regulatory T cells (Tregs) and demonstrate an interleukin-17 phenotype that enhances OC activation. In univariate analyses of factors mediating bone destruction, levels of cytokines that selectively induce and maintain the Th17 phenotype tightly correlated with the extent of bone disease in myeloma. In contrast, MILs activated under conditions that skew toward a Th1 phenotype ...
Multiple myeloma (MM), a plasma cell dyscrasia, is the most common primary malignancy of the bone marrow.The etiology of myeloma is largely unknown, although genetic predisposition and environmental factors have been speculated. MM arises from malignant plasma cells that clonally expand and accumulate in the bone marrow. These clonal plasma cells produce high levels of monoclonal immunoglobulins. Plasma cell dyscrasias are classified as monoclonal gammopathy of undetermined significance, solitary plasmacytoma, smoldering myeloma, active myeloma, extra-skeletal myeloma, or plasma cell leukemia.. In 2015 an estimated 26,850 adults (14,090 men and 12,760 women) in the United States will be diagnosed with multiple myeloma. It is estimated that 11,240 deaths (6,240 men and 5,000 women) from this disease will occur this year.. In recent years, new and more effective drugs have become available for the treatment of MM. Such drugs have been evaluated together and in combination with older agents, ...
Title:Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis. VOLUME: 14 ISSUE: 4. Author(s):J. Abdi, J. Garssen and F. Redegeld. Affiliation:Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, P.O. Box 80082, 3508 TB Utrecht, The Netherlands.. Keywords:Bone marrow, drug resistance, inflammation, multiple myeloma, toll like receptors.. Abstract:Multiple myeloma (MM) is a clonal neoplasm characterized by expansion of malignant plasma cells in the bone marrow causing various complications including osteolytic lesions and impaired immune function. It has recently been reported that human myeloma cells express multiple Toll-like receptors (TLRs), and their activation-induced functional responses show heterogeneity among cell lines and patient samples. TLRs are critical germ-line encoded molecules expressed in immune cells as well as in a variety of cancer cells. In multiple myeloma, they may ...
The introduction of three new drugs for multiple myeloma - Velcade® (bortezomib), Revlimid® (lenalidomide), and Thalomid® (thalidomide) - has improved outcomes among patients with newly-diagnosed multiple myeloma as well as patients with relapsed or refractory multiple myeloma.. Velcade® (bortezomib): Velcade is a targeted therapy that inhibits the activities of a group of proteins, called proteasomes. These proteins are found in virtually all cells, but are particularly important for allowing myeloma cancer cells to survive and grow. By inhibiting the proteasomes, Velcade kills cancer cells and reduced overall cancer growth.. Important support for the use of Velcade in the treatment of relapsed multiple myeloma came from a phase III clinical trial known as the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial. The study enrolled more than 600 patients with relapsed multiple myeloma. Half the patients were treated with Velcade and half were treated with high-dose ...
End stage multiple myeloma is the final stage of advanced multiple myeloma. According to MedlinePlus, the symptoms of end stage multiple myeloma include vomiting, nausea, urination problems, numbness...
Results The most common sites for extramedullary disease at diagnosis were skin and soft tissue whereas liver involvement was the striking feature in extramedullary disease at disease relapse or progression. Regardless of therapy, extramedullary disease was associated with shorter progression-free and overall survival, as well as the presence of anemia, thrombocytopenia, elevated serum lactate dehydrogenase, cytogenetic abnormalities, and high-risk features in 70-and 80-gene risk models in univariate analysis. Multivariate analysis with logistic regression revealed that this disease feature was more prevalent in patients with an elevated centrosome index, as determined by gene expression profiling, as well as in myeloma molecular subtypes that are more prone to relapse. These include the MF subtype (also called the MAF subtype, associated with over-expression of the MAF gene seen with chromosome translocation 14;16 or 14;20) and the PR subtype (also called the Proliferation subtype, ...
Bone complications: In 70% of multiple myeloma cases, the bones develop multiple holes, which explains why the disease is referred to as multiple myeloma. The holes are referred to as osteolytic lesions, which cause the bones to be fragile and subject to fractures. Osteolytic lesions are caused by the rapid growth of myeloma cells, which push aside normal bone-forming cells, preventing them from repairing general wear and tear of the bones. Under normal circumstances, cells called osteoclasts destroy dead and dying bone. Multiple myeloma causes the secretion of osteoclast-activating factor, a substance that stimulates osteoclasts.. Multiple myeloma involving the bone can cause pain, fracture and other significant problems for patients. Management of bone involvement is an integral part of the overall treatment strategy for multiple myeloma. The first objective of treatment of bone complications is to prevent new bone disease from developing or progression from existing bone lesions to ...
This article was originally published by Cancer Health New drugs to treat multiple myeloma are producing better results for patients, with fewer side effects.. For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested by Dana-Farber scientists have gained approval from the U.S. Food and Drug Administration (FDA) or taken a step toward approval after posting solid results in clinical trials.. The drugs are the fruit of years of research into improving treatment for multiple myeloma, a cancer of white blood cells known as plasma cells in the bone marrow. Many of the new agents are biologically derived - made from substances such as proteins and antibodies found in living things - and target biological mechanisms in a very specific, targeted fashion. Dana-Farber researchers have played a key role in these efforts.. These are each powerful examples of how ...
Despite recent advances in the treatment of multiple myeloma, the disease constantly relapses and is still considered as incurable. The current knowledge about the biological mechanisms underlying resistance to the different class of drugs in multiple myeloma remains poor. The primary objective of the MYRACLE (Myeloma Resistance And Clonal Evolution) cohort, a multicenter prospective cohort of patients with multiple myeloma, is to address this limitation. We here describe the study background, design and methods used for this cohort. All patients (| 18 year old) diagnosed with de novo or relapsed multiple myeloma and treated in two hematology department from west of France are included in the MYRACLE cohort. Patients provide a signed informed to be included in the study. All subjects are followed until refusal to participate in the study or death. The MYRACLE cohort prospectively collects data on socio-economic status, medical status, imaging, prognosis factors, MM therapies and associated events
MM patients develop chemoresistance, and increasing the concentrations of cytotoxic drugs fails to significantly improve the therapeutic response. One hypothesis for the development of chemoresistance is related to acquired resistance of the tumor cells to apoptosis (34) , allowing tumors to withstand high levels of chemotherapy. Tumor cells that are resistant to apoptosis also exhibit increased proliferative capacity. Wang et al. (35) reported that activation of NF-κB in response to chemotherapy is a principal mechanism of tumor chemoresistance. Inhibition of such inducible NF-κB activation enhances apoptosis. Increased activity of NF-κB proteins has been reported in solid tumors resistant to chemotherapy (36) . In this report, we found that the activity of NF-κB was elevated in MM tumor cells. The activity of NF-κB appeared to be higher in chemoresistant MM cell lines compared with chemosensitive ones, although the difference was not always consistent between chemosensitive versus ...
The proteasome inhibitor bortezomib has a striking clinical benefit in patients with multiple myeloma. It is unknown whether the bone marrow microenvironment directly contributes to the dramatic response of myeloma cells to proteasome inhibition in vivo. We have used the well-characterized 5TGM1 murine model of myeloma to investigate myeloma growth within bone and response to the proteasome inhibitor bortezomib in vivo. Myeloma cells freshly isolated from the bone marrow of myeloma-bearing mice were found to have an increase in proteasome activity and an enhanced response to in vitro proteasome inhibition, as compared with pre-inoculation myeloma cells. Treatment of myeloma-bearing mice with bortezomib resulted in a greater reduction in tumor burden when the myeloma cells were located within the bone marrow when compared with extra-osseous sites. Our results demonstrate that myeloma cells exhibit an increase in proteasome activity and an enhanced response to bortezomib treatment when located within the
Multiple myeloma is a hematologic malignancy associated with the development of a destructive osteolytic bone disease. Mathematical models are developed for normal bone remodeling and for the dysregulated bone remodeling that occurs in myeloma bone disease. The models examine the critical signaling between osteoclasts (bone resorption) and osteoblasts (bone formation). The interactions of osteoclasts and osteoblasts are modeled as a system of differential equations for these cell populations, which exhibit stable oscillations in the normal case and unstable oscillations in the myeloma case. In the case of untreated myeloma, osteoclasts increase and osteoblasts decrease, with net bone loss as the tumor grows. The therapeutic effects of targeting both myeloma cells and cells of the bone marrow microenvironment on these dynamics are examined. The current model accurately reflects myeloma bone disease and illustrates how treatment approaches may be investigated using such computational approaches. This
TY - JOUR. T1 - Smoldering multiple myeloma risk factors for progression. T2 - a Danish population-based cohort study. AU - Sørrig, Rasmus. AU - Klausen, Tobias W. AU - Salomo, Morten. AU - Vangsted, Annette J. AU - Østergaard, Brian. AU - Gregersen, Henrik. AU - Frølund, Ulf Christian. AU - Andersen, Niels F. AU - Helleberg, Carsten. AU - Andersen, Kristian T. AU - Pedersen, Robert S. AU - Pedersen, Per. AU - Abildgaard, Niels. AU - Gimsing, Peter. AU - Danish Myeloma Study Group. N1 - This article is protected by copyright. All rights reserved.. PY - 2015/12/29. Y1 - 2015/12/29. N2 - Several risk scores for disease progression in Smoldering Multiple Myeloma (SMM) patients have been proposed, however, all have been developed using single center registries. To examine risk factors for time to progression (TTP) to Multiple Myeloma (MM) for SMM we analyzed a nationwide population-based cohort of 321 newly diagnosed SMM patients registered within the Danish Multiple Myeloma Registry between 2005 ...
Multiple myeloma is a cancer of the plasma cells. People with the condition have an increase of abnormal plasma cells (myeloma cells) in their bone marrow, monoclonal protein in their blood and, often, osteolytic bone lesions. As the disease progresses, symptoms of anemia, fatigue, weakness, fractures, bone pain, increased blood calcium, kidney problems, recurrent infections and bleeding are common. The median survival rate is three to four years. The American Cancer Society estimates 20,000 people are diagnosed with multiple myeloma in the U.S. each year.. People with MGUS do not have symptoms associated with multiple myeloma. The disorder is diagnosed by laboratory tests that indicate an increase in M proteins in the blood and elevated bone marrow plasma cells.. I recognized the importance of a having a laboratory that could identify the type of protein and be able to distinguish monoclonal from polyclonal proteins, says Dr. Kyle. I visited the National Institutes of Health and Columbia ...
Earn CME: https://naccme.com/program/7312In this presentation from the Looking for One in a Million: Is MRD the New Primary Goal for Multiple Myeloma Treatment? symposium, Dr. C. Ola Landgren argues that MRS is new primary goal for multiple myeloma treatment.© 2018 Imedex, an HMP Company - Multiple Myeloma
Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.
Current criteria for differential diagnosis of multiple myeloma (MM), Monoclonal gammopathy of undetermined significance (MGUS), and smoldering multiple myeloma (SMM) are included in the 2003 guidelines by the International Myeloma Working Group (IMWG). An updated version was then published in 2014, highlighting the importance of serum free light chain (sFLC) detection, as well as the κ/λ ratio as excellent indicators of clonality. At present, two commercial assays for sFLC quantification are available: the Freelite™ assay and the N-Latex assay. The first was developed by The Binding Site based on a mixture of polyclonal antibodies directed against a variety of FLC epitopes. It may be run on a wide range of nephelometers, as well as on turbidimeters. The second method was developed by Siemens and runs exclusively on Siemens instruments. It employs a probe mixture of mouse monoclonal antibodies. The aim of our study was to evaluate sFLC measurement and calculated κ/λ ratio in 85 patients with
Bone destruction is a hallmark of myeloma and affects 80% of patients. Myeloma cells promote bone destruction by activating osteoclasts. In investigating the underlying mechanism, we found that C-reactive protein (CRP), a protein secreted in increased amounts by hepatocytes in response to myeloma-derived cytokines, activated myeloma cells to promote osteoclastogenesis and bone destruction in vivo. In mice bearing human bone grafts and injected with multiple myeloma cells, CRP bound to surface CD32 (also known as FcγRII) on myeloma cells, which activated a pathway mediated by the kinase p38 MAPK and the transcription factor Twist that enhanced the cells secretion of osteolytic cytokines. Furthermore, analysis of clinical samples from newly diagnosed myeloma patients revealed a positive correlation between the amount of serum CRP and the number of osteolytic bone lesions. These findings establish a mechanism by which myeloma cells are activated to promote bone destruction and suggest that CRP ...
Source: Myeloma Research News. People with advanced multiple myeloma and diffuse large B-cell lymphoma (DLBCL) will soon be able to access Xpovio (selinexor) outside the U.S. through a managed access program.. This program, also known as a named patient program, allows patients and doctors in countries where a medicine is not yet approved or available access to them, provided the medicine is approved in one other country.. Karyopharm Therapeutics, the developer of Xpovio, partnered with Clinigen to open such a program. Under the agreement, Clinigen will distribute and facilitate access to Xpovio in 49 countries across Central and South America, Africa, Asia, and Europe, it announced in a press release.. The therapy will be exclusively available to patients with either multiple myeloma or DLBCL, for whom Xpovio has been approved in the U.S.. Physicians can obtain the details of Xpovios named patient program by contacting Clinigens customer service team by phone (+44-1932-824-123, or ...
Multiple Myeloma (90) Multiple Myeloma Awareness (36) Bone Marrow Transplant (28) Michigan Football (27) Dominate (25) Myeloma Mondays (24) Stem Cell Transplant (24) Multiple Myeloma Survivor Stories (19) Chemo (15) M-Protein (15) Dr. J (14) MM (12) Dexamethasone (11) BMT (10) Ocean (9) UMHS (9) domiNATION (9) Cancer Kicker (8) Hope (8) IgG (8) M Spike (8) MM Awareness (8) Revlimid (8) Story Time (8) Velcade (8) Cancer Kicker Foundation (7) Chemotherapy (7) Dominate Gear (7) M-Spike (7) Ruby (7) Young with Myeloma (7) Dominate Life (6) Multiple Myeloma Bracelets (6) Thankful Thursdays (6) Cancer Kicker Bracelets (5) Complete Response (5) Dominate Myeloma (5) Doxil (5) Iris (5) Michigan Faithful (5) Phil and Cassie Plus Cancer Show (5) RVDD (5) SCT (5) UAMS (5) Big House Big Heart run (4) Bone Marrow Biopsy (4) CancerKicker (4) Consolidation (4) Constipation (4) Cytoxan (4) ER (4) Infusion Center (4) M Protein (4) MMRF (4) Maintenance Therapy (4) Stem Cell Collection (4) Stomach Lava (4) Survivor ...
The main finding reported here is that IL-6-induced proliferation may be dependent on c-Met signaling in myeloma cells. The potentiating effect of HGF/c-Met on IL-6 signaling could be explained by two mechanisms: (i) IL-6 increased the level of c-Met on the cell surface of myeloma cells making cells more sensitive to HGF; and (ii) IL-6 relied on HGF/c-Met to fully activate the Ras-MAPK pathway possibly through Shp2 activation.. HGF is found in bone marrow plasma of both healthy subjects and myeloma patients (5), and bone marrow stromal cells constitutively produce HGF (34). Moreover, syndecan-1 binds HGF on the surface of myeloma cells (5) bringing HGF in close proximity of its receptor c-Met. Immunohistochemical staining for HGF on bone marrow biopsies revealed that plasma cells from almost all myeloma patients stained positive for HGF (K. W. Wader, unpublished data). In this context, the IL-6-induced increase in c-Met expression as shown here may become vital for HGF sensitivity and growth ...
The treatment of multiple myeloma is focused on treating the underlying disease (the increased number of abnormal plasma cells). Managing the symptoms and other medical problems resulting from the increased numbers of plasma cells and abnormal proteins is equally important.. The following complications of multiple myeloma have specific treatments available:. Bone complications: In 70% of multiple myeloma cases, the bones develop multiple holes, which explains why the disease is referred to as multiple myeloma. The holes are referred to as osteolytic lesions, which cause the bones to be fragile and subject to fractures. Osteolytic lesions are caused by the rapid growth of myeloma cells, which push aside normal bone-forming cells, preventing them from repairing general wear and tear of the bones. Under normal circumstances, cells called osteoclasts destroy dead and dying bone. Multiple myeloma causes the secretion of osteoclast-activating factor, a substance that stimulates ...
Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e105-e118 ...
An investigational new class of drugs, the anti-CD38 monoclonal antibodies, could be the next major advance in the treatment of multiple myeloma. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6-9, 2014, in San Francisco, California.. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of the bodys immune system. In the U.S., approximately 70,000 people are living with multiple myeloma and approximately 24,000 new individuals are diagnosed annually. Patients with multiple myeloma have increased numbers of abnormal plasma cells that may produce increased quantities of dysfunctional antibodies detectable in the blood and/or urine. Patients with multiple myeloma who have become refractory-or resistant-to the drugs Revlimid® (lenalidomide) and Velcade® (bortezomib) have limited treatment options. There is no standard treatment for these patients and they typically have a poor ...
TY - JOUR. T1 - The blood B-cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements. AU - Bergsagel, P. L.. AU - Masellis Smith, A.. AU - Belch, A. R.. AU - Pilarski, L. M.. PY - 1994/1/1. Y1 - 1994/1/1. N2 - Previous reports have described the phenotypic and functional properties of monotypic late stage B cells in the blood of patients with multiple myeloma and have speculated that these B cells represent a malignant circulating component of myeloma. Here we show that blood B cells have IgH rearrangements identical to those expressed by the bone marrow plasma cells by using Ig Fingerprint and Allele-Specific Oligomer (ASO) polymerase chain reaction (PCR) methods. DNA from purified blood B cells and bone marrow plasma cells taken at the same time, and blood B cells taken at subsequent patient visits was amplified using consensus IgH primers, or ASO primers. In 10/16 patients, a single IgH rearrangement was amplified from the bone marrow plasma ...
IgM multiple myeloma is rare disorder, which has clinical, laboratory and radiological manifestations that are consistent with both multiple myeloma and Waldenstroms macroglobulinaemia. An 83 years Welsh lady presented with clinical and radiological features consistent with spinal cord compression. Further investigations confirmed the diagnosis of IgM multiple myeloma. Following localized radiotherapy and five courses of melphalan and prednisolone, the patient achieved partial remission of her myeloma. Later on, the patient had disease progression in the form of rising serum IgM level and the development of multiple plasmacytomas. She was treated with thalidomide, cyclophosphamide, dexamethasone and radiotherapy, which resulted in the control of her disease for one year. To our knowledge, this is the second case of IgM myeloma presenting with a plasmacytoma and the first case of IgM myeloma presenting with cord compression caused by plasmacytomas. Unlike other types of multiple myeloma IgM myeloma is
Between Nov 8, 2007, and June 9, 2010, 125 patients were enrolled and underwent randomisation. 119 patients comprised the per-protocol population and were randomly assigned to receive either lenalidomide plus dexamethasone (n=57) or observation (n=62). The cutoff date for this update was June 30, 2015. Median follow-up for surviving patients was 75 months (IQR 67-85).. Lenalidomide plus dexamethasone continued to provide a benefit on time to progression compared with observation (median time to progression not reached [95% CI 47 months-not reached] vs 23 months [16-31]; hazard ratio [HR] 0·24 [95% CI 0·14-0·41]; p,0·0001). Progression to multiple myeloma occurred in 53 (86%) of 62 patients in the observation group compared with 22 (39%) of 57 patients in the treatment group. At data cutoff, ten (18%) patients had died in the treatment group and 22 (36%) patients had died in the observation group; median overall survival from the time of study entry had not been reached in either group (95% ...
TY - JOUR. T1 - Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. AU - Landgren, Ola. AU - Hofmann, Jonathan N.. AU - McShane, Charlene. AU - Santo, Loredana. AU - Korde, Neha AU - Hultcrantz, Malin. AU - Mailankody, Sham. AU - Kazandjian, Dickran. AU - Murata, Kazunori. AU - Thoren, Katie. AU - Ramanathan, Lakshmi. AU - Dogan, Ahmet. AU - Rustad, Even. AU - Lu, Sydney X.. AU - Akhlaghi, Theresia. AU - Kristinsson, Sigurdur Y.. AU - Björkholm, Magnus. AU - Devlin, Sean AU - Purdue, Mark P.. AU - Pfeiffer, Ruth M.. AU - Turesson, Ingemar. PY - 2019/7/18. Y1 - 2019/7/18. N2 - Importance Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS). Risk models that estimate the risk of progression from MGUS to multiple myeloma use data from a single time point, usually the initial workup. Objective To longitudinally investigate the alterations of serum immune markers with stable ...
Long-lived bone marrow plasma cells (BMPCs) are a persistent and essential source of protective antibodies1-7. Individuals who have recovered from COVID-19 have a substantially lower risk of reinfection with SARS-CoV-28-10. Nonetheless, it has been reported that levels of anti-SARS-CoV-2 serum antibodies decrease rapidly in the first few months after infection, raising concerns that long-lived BMPCs may not be generated and humoral immunity against SARS-CoV-2 may be short-lived11-13. Here we show that in convalescent individuals who had experienced mild SARS-CoV-2 infections (n = 77), levels of serum anti-SARS-CoV-2 spike protein (S) antibodies declined rapidly in the first 4 months after infection and then more gradually over the following 7 months, remaining detectable at least 11 months after infection. Anti-S antibody titres correlated with the frequency of S-specific plasma cells in bone marrow aspirates from 18 individuals who had recovered from COVID-19 at 7 to 8 months after infection. S
1. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-9. doi: 10.1056/NEJMoa054494 16571879. 2. Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(14):1478-85. doi: 10.1182/blood-2018-04-839480 30012636. 3. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5 25439696. 4. Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292-5. doi: 10.1182/blood-2012-07-445304 23047823. 5. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, ...
TY - JOUR. T1 - Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. AU - Genuardi, Maurizio. AU - Palumbo, Antonio. AU - Larocca, Alessandra. AU - Genuardi, Mariella. AU - Kotwica, Katarzyna. AU - Gay, Francesca. AU - Rossi, Davide. AU - Benevolo, Giulia. AU - Magarotto, Valeria. AU - Cavallo, Federica. AU - Bringhen, Sara. AU - Rus, Cecilia. AU - Masini, Luciano. AU - Lacobelli, Massimo. AU - Gaidano, Gianluca. AU - Mitsiades, Constantine. AU - Anderson, Kenneth. AU - Boccadoro, Mario. AU - Richardson, Paul. PY - 2010. Y1 - 2010. N2 - Background Defibrotide is a novel orally bioavailable polydisperse oligonucleotide with anti-thrombotic and anti-adhesive effects. In SCID/NOD mice, defibrotide showed activity in human myeloma xenografts. This phase I/II study was conducted to identify the most appropriate dose of defibrotide in combination with melphalan, prednisone and thalidomide in patients with relapsed and ...
The International Myeloma Foundation is dedicated to finding a cure for multiple myeloma through global research, and offers myeloma treatment guidelines and support.
The International Myeloma Foundation is dedicated to finding a cure for multiple myeloma through global research, and offers myeloma treatment guidelines and support.
BACKGROUND: Several observational studies have investigated autoimmune disease and subsequent risk of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Findings have been largely inconsistent and hindered by the rarity and heterogeneity of the autoimmune disorders investigated. A systematic review of the literature was undertaken to evaluate the strength of the evidence linking prior autoimmune disease and risk of MGUS/multiple myeloma. METHODS: A broad search strategy using key terms for MGUS, multiple myeloma, and 50 autoimmune diseases was used to search four electronic databases (PubMed, Medline, Embase, and Web of Science) from inception through November 2011. RESULTS: A total of 52 studies met the inclusion criteria, of which 32 were suitably comparable to perform a meta-analysis. Any autoimmune disorder was associated with an increased risk of both MGUS [n = 760 patients; pooled relative risk (RR) 1.42; 95% confidence interval (CI), 1.14-1.75] and multiple ...
Sequential sera from 45 patients with multiple myeloma (MM) and from 6 patients with solid tumors but normal bone marrows who received cyclophosphamide, 15 mg/kg/day for 4 days, were assayed for their effects on tritiated thymidine (3H-TdR) incorporation by normal bone marrow cells and malignant plasma cells. Pretreatment sera from 23 of the 45 patients with MM inhibited normal marrow cell proliferation relative to the effects of normal sera. Of these 45 sera, 30 inhibited plasma cell proliferation. This humoral inhibition was overcome by the induction of humoral stimulation at a predictable time during chemotherapy. The sera obtained sequentially from patients with MM and patients with normal bone marrows increased 3H-TdR uptake by both cell types by days 12-15 of therapy. Sequential changes in malignant marrow plasma cell 3H-TdR labeling indices paralleled the changes in serum activity, with an increased tumor cell growth fraction occurring at the time of peak serum stimulatory activity. The ...
polyneuropathy (1 grade 3), edema (1 grade 3), and pyrexia (1 grade 1). No anti-AMG 420 antibodies were detected at doses up to 800 μg/d. Six patients had a complete response, 1 each at 6.5, 100, and 200 µg/d, and 3 at 400 µg/d; responses were ongoing for the past 3 months. There also were 2 partial remissions, a partial response at 50 µg/d, and a very good partial response at 800 µg/d. All 3 patients treated at 400 µg/d had an MRD-negative complete response.. Clinical Implications: AMG 420 showed evidence of clinical activity in patients with relapsed or refractory multiple myeloma. No major toxicities were observed up to 400 µg/d, and that is the recommended dose for further investigation; dose-limiting toxicities at 800 µg/d were cytokine-release syndrome and peripheral polyneuropathy. (Also, refer to Abstract 592, which highlights the activity of AMG 701, another anti-BCMA bispecific T-cell engager.4) The bispecific T-cell engager technology has already shown efficacy in leukemia and ...
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. (Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, ...
The International Myeloma Foundation (IMF) is an American non-profit organization serving patients with myeloma, a cancer of plasma cells in the bone marrow. The IMF also provides support and information for family members, caregivers of myeloma patients, physicians and nurses. The organization is dedicated to improving the quality of life for all myeloma patients by focusing on four key areas: research, education, support, and advocacy. Founded in 1990 by Brian Novis, Susie Novis, and Brian G.M. Durie, M.D., IMF is a 501(c)3 resource for both patients and caregivers, offering programs that include educational seminars, a patient hotline, multilingual publications, government advocacy, and a web-based Personal Information Management system for recording care and treatment. The IMF is based in North Hollywood, California, and, according to its 2013 annual report, has a membership of 350,000 people in 140 countries. Its motto is Improving lives - Finding the cure. The IMF was founded in 1990 by ...
FDA has accepted Karyopharm Therapeutics Inc.s supplemental New Drug Application seeking approval for Xpovio-its first-in-class, oral selective inhibitor of nuclear export compound, as a new treatment for patients with multiple myeloma after at least one prior line of therapy. Karyopharm expects a decision from the FDA regarding this sNDA before the end of the first quarter of 2021.. If approved, we believe XPOVIO will become an important new, oral, once-weekly treatment option, used in combination with once-weekly Velcade®, for patients with multiple myeloma after at least one prior line of therapy, Sharon Shacham, founder, president and chief scientific officer of Karyopharm, said in a statement.. Xpovio was previously approved by FDA for treatment of patients with penta-refractory multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma. The company also plans to submit a Marketing Authorization Application to the European Medicines Agency later this year for this same ...
Multiple myeloma is a difficult-to-treat hematologic malignancy, where the MYC oncoprotein often plays a key role by stimulating ribosome production and up-regulating protein translation to satisfy the needs of rapidly proliferating cancer cells. By performing a high-throughput screen, Manier et al. determined that small-molecule rocaglate derivatives are active in multiple myeloma. The authors focused on one lead rocaglate derivative and showed that it reversed the effects of MYC, blocked excessive translation, induced tumor cell apoptosis, and decreased tumor cell proliferation. The treatment was safe and effective in multiple mouse models, suggesting rocaglates as potential therapeutic candidates for multiple myeloma. ...
Carlos Fernandez de Larrea, MD, PhD from the Hospital Clínic de Barcelona, Barcelona, Spain gives an overview of his talk on response assessment in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. According to Dr de Larrea, the response assessment in MM is crucial. It is important to establish whether a patient has achieved complete remission (CR) and to identify patients who are relapsing or progressing after different lines of treatment. Dr de Larrea further discusses the various techniques used to assess response, such as electrophoresis in serum and urine and imaging techniques. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
TY - JOUR. T1 - Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma. T2 - Prognostic factors and unique toxicity profile. AU - Hattori, Yutaka. AU - Okamoto, Shin Ichiro. AU - Shimada, Naoki. AU - Kakimoto, Tsunayuki. AU - Morita, Kunihiko. AU - Tanigawara, Yusuke. AU - Ikeda, Yasuo. PY - 2008/6. Y1 - 2008/6. N2 - We previously reported a pilot study of thalidomide monotherapy for Japanese patients with refractory or relapsed multiple myeloma. In the present work, we have extended this clinical trial to a single-institute phase 2 study with a larger number of patients and longer follow-up time. New information on the optimal dose and prognostic factors as well as the correlation of toxicities with treatment schedule was obtained. Fifteen of 56 (27%) patients achieved a partial response, including three cases with near-complete remission. Most patients suffered toxicities at a dose of 400 mg per day, but there was no clear dose-response ...
Multiple myeloma (plasma cell neoplasm) is a rare type of cancer that results in the uncontrolled production of one type of white blood cell (plasma cell) in the bone marrow. The cancer cells can crowd out normal blood cells, causing a reduction in red blood cells (anemia). The overproduction of plasma cells causes an...
TY - JOUR. T1 - Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. AU - Basak, Grzegorz W.. AU - Jaksic, Ozren. AU - Koristek, Zdenek. AU - Mikala, Gabor. AU - Basic-Kinda, Sandra. AU - Mayer, Jiri. AU - Masszi, Tamas. AU - Giebel, Sebastian. AU - Labar, Boris. AU - Wiktor-Jedrzejczak, Wieslaw. PY - 2011/6/1. Y1 - 2011/6/1. N2 - A proportion of patients with multiple myeloma (MM) who have already undergone autologous stem cell transplantation (autoSCT) might benefit from a further transplantation. For this, they might need to undergo another round of stem cell mobilization. We analyzed retrospectively the outcomes of stem cell mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) in a group of 30 patients who had undergone autoSCT previously, and in 46 other patients. The previously transplanted patients were significantly different from the remaining patients with respect to the ...
I dont know about you, but I am fielding more and more questions from multiple myeloma patients and caregivers about where to find financial assistance.Here is a link to a site/organization I havent tried called Patient Advocate Foundation Co-Pay Relief:Patient Advocate Foundations Co-Pay Relief (CPR) for Multiple Myeloma Patients.I have personally been aproved by the. ...
TY - JOUR. T1 - 99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients. AU - Fallahi, Babak. AU - Beiki, Davood. AU - Mousavi, Seyed Asadollah. AU - Gholamrezanezhad, Ali. AU - Eftekhari, Mohammad. AU - Fard-Esfahani, Armaghan. AU - Alimoghaddam, Kamran. AU - Mirpour, Sahar. AU - Eskandarian, Alireza. AU - Saghari, Mohsen. PY - 2009/9/1. Y1 - 2009/9/1. N2 - Multi-drug resistance (MDR) is a major challenge in the treatment of multiple myeloma (MM). There is low sensitivity of technetium-99m methoxy isobutyl isonitrile (99mTc-MIBI) whole body scan (WBS) in the detection of active MM lesions, because 99Tc-MIBI is washed out from malignant cells in the presence of P-glycoprotein (PGP). The objective of the present cohort study was to evaluate of 99mTc-MIBI WBS in the prediction of MDR in MM patients during a course of one year follow up. Thirty four patients with MM (25 male, 9 female of mean age 54.12±11.46 years) entered ...
Treatment of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Bone Cancer & Myeloma Research West Hollywood, CA Clinical Consequences of Myeloma Bone Disease Pathological
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.. ...
However this time I am more apprehensive of the new MRD test. All the current tests for light chains, lesions, bone marrow biopsy, M spike, etc. have always indicated that I was in CR. The MRD test is a far more sensitive test, and will be able to see if there are any myeloma cells left in my system. So a MRD negative result would confirm that my disease is under control based on the most sensitive tests yet available for multiple myeloma diagnostics. And a positive result would just SUCK. Other diseases use a MRD test to determine if a patients treatment has been successful, and when or if it should be changed. MRD is used for acute lymphoblastic leukemia (ALL), and MRD status is one of the most powerful predictors of disease-free and overall survival for children with ALL. The promise for myeloma is that we are able to use this test in the same manner. The International Myeloma Foundation has developed a program called the Black Swan Initiative intended to use a test for MRD with enough ...
TY - JOUR. T1 - Relapse of multiple myeloma presenting as lower lip numbness. AU - Al-Riyami, Yusra M.. AU - Bakathir, Abdulaziz. AU - Al-Farsi, Khalil. AU - Al-Azri, Faisal. PY - 2016/11/1. Y1 - 2016/11/1. N2 - Multiple myeloma (MM) is an uncommon malignancy characterised by the proliferation of clonal plasma cells. There are few published reports describing the extramedullary presentation of MM manifesting primarily in the head and neck region. In addition, the occurrence of an isolated relapse of MM in these sites is exceedingly rare. We report a 56-year-old female who presented to the Sultan Qaboos University Hospital, Muscat, Oman, in 2010 with sudden-onset numbness of the lower lip. She had a history of MM in remission following chemotherapy and a bone marrow transplant. Clinical and radiographic examinations were indicative of a possible relapse of MM, which was subsequently confirmed by bone marrow aspiration and histopathological evaluation. This unique case highlights the unusual site ...
Background: Deleted in liver cancer-1 (DLC-1) is a tumour suppressor gene that is inactive in liver carcinogenesis. It encodes a ρ-guanosine triphosphatase-activating protein (ρ-GAP) and maps to one of the deleted regions (8p21.3-22). Little is known, however, about the methylation status of the DLC-1 promoter in myeloma cells.. Aim: To identify whether methylation of DLC-1 was associated in pathogenesis of multiple myeloma.. Methods: Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect DLC-1 transcripts in RPMI 8226, U266, OPM-2 and XG-2 cell lines. The methylation status was determined by methylation-specific PCR followed by bisulphite DNA sequencing in these four cell lines and in the bone marrow of 14 patients with multiple myeloma and 4 normal patients. DLC-1 mRNA expression in cells with or without treatment with 5-aza-deoxycytidine (5-aza-CdR) or trichostatin A (TSA) was investigated by real-time RT-PCR.. Results: RPMI 8226 and U266 showed complete methylation and ...
The Role of High Dose Chemotherapy With Autologous Stem Cell Rescue in Multiple Myeloma in the Era of Conventional Cytotoxic Chemotherapy. Before the introduction of proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs), high dose melphalan with ASCT following induction therapy was considered the standard approach for transplant-eligible patients with newly diagnosed MM. The first randomized controlled trial from the Intergroupe Francais du Myelome (IFM90), published in 1996, randomized newly diagnosed MM patients to an older chemotherapy regimen (vincristine/carmustine, cyclophosphamide, prednisone alternating with carmustine, vincristine, adriamycin, prednisone; VMCP/BVAP) for 12 cycles versus 4 to 6 cycles of VMCP/BVAP followed by high dose therapy with autologous bone marrow transplant.1 Those patients randomized to the transplant arm compared with the high dose chemotherapy arm had a superior 5-year event-free survival (EFS) (28% versus 10%, respectively, P = .01) and OS (52% ...
Maintenance Therapy with Immunomodulatory Drugs after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Assessment of whole body MRI and sestamibi technetium-99m bone marrow scan in prediction of multiple myeloma disease progression and outcome: a prospective comparative study Journal Articles Refereed ...
Multiple myeloma[edit]. An increased incidence of Duffy antigen has been reported in patients with multiple myeloma compared ... phenotype in patients with multiple myeloma compared to healthy controls". Hematol Oncol. 27 (1): 50-1. doi:10.1002/hon.887. ... CS1 maint: multiple names: authors list (link) *^ Oliveira TY, Harris EE, Meyer D, Jue CK, Silva WA (2012). "Molecular ...
Multiple Myeloma. *Overwhelming infections. *Lymphoma. *Myelofibrosis. *Dyskeratosis congenita. *Myelodysplastic syndrome. * ...
Multiple myeloma. 8. $1.87 billion. Cetuximab. Erbitux. Merck KGaA, Bristol-Myers Squibb. Colon and head and neck cancer. ... Gray OM, McDonnell GV, Forbes RB (Aug 2006). "A systematic review of oral methotrexate for multiple sclerosis". Multiple ... CS1 maint: Multiple names: authors list (link). *^ a b Gray O, McDonnell GV, Forbes RB (2004). Gray, Orla, ed. "Methotrexate ... CS1 maint: Multiple names: authors list (link). *^ Lodish H, Berk A, Zipursky SL, et al. (2000). Molecular Cell Biology. 4th ...
Multiple Myeloma), which was linked to toxic water exposure on Camp Lejeune. This is believed to be the first time the ... multiple myeloma; myleodysplasic syndromes; renal toxicity; hepatic steatosis; female infertility; miscarriage; scleroderma; ...
Multiple myeloma can cause a proteinuria that is not accompanied by hypoalbuminemia, which is an important aid in making a ... Multiple myeloma: renal impairment is caused by the accumulation and precipitation of light chains, which form casts in the ... CS1 maint: Multiple names: authors list (link) *^ According to MedlinePlus, avascular necrosis is the death of the bone caused ... CS1 maint: Multiple names: authors list (link) *^ "Valores normales de proteína en orina de 24 horas". Retrieved 24 August 2012 ...
Multiple myeloma GlaxoSmithKline cedazuridine and decitabine[15] CMML Astex Pharmaceuticals Extensions[edit]. Extension to rare ...
Multiple myeloma (MM)Edit. Main article: Multiple myeloma. Alcohol has been suggested as a possible cause of multiple myeloma,[ ... January 2007). "Alcohol consumption and risk of Hodgkin's lymphoma and multiple myeloma: a multicentre case-control study". ... Alcohol consumption and risk of Hodgkin's lymphoma and multiple myeloma: a multicentre case-control study' by Gorini et al". ... CS1 maint: Multiple names: authors list (link). *^ "Cancer warning labels to be included on alcohol in Ireland, minister ...
In 1998 thalidomide was approved by the U.S. Food and Drug Administration (FDA) for use in newly diagnosed multiple myeloma (MM ... This is believed to be a main component of the mechanism in vivo by which thalidomide inhibits multiple myeloma. Additionally, ... Armoiry, X.; Aulagner, G.; Facon, T. (1 June 2008). "Lenalidomide in the treatment of multiple myeloma: a review". Journal of ... July 1994). "Bone marrow angiogenesis and progression in multiple myeloma". Br. J. Haematol. 87 (3): 503-8. doi:10.1111/j.1365- ...
Rajkumar, S. Vincent (2018). "Multiple Myeloma". In Hensley, Martee L.; Milowsky, Matthew I.; Rajkumar, S. Vincent; Schuetze, ... Panobinostat inhibits multiple histone deacetylase enzymes, a mechanism leading to apoptosis of malignant cells via multiple ... On 23 February 2015 it received FDA accelerated approval for use in patients with multiple myeloma, and on 28 August 2015 it ... "Panobinostat chemotherapy regimen for multiple myeloma". HemOnc.org LLC. "Farydak product details". European Medicines Agency. ...
Bloodgood invited Geschickter to work on multiple myeloma, and Geschickter invited his classmate Murray Copeland to work with ... Moehler, Thomas (2011-01-01). Multiple Myeloma. Springer. ISBN 978-3-540-85772-3. Retrieved 2013-01-02. Null, Gary; McDonald, ...
"Pomalyst (Pomalidomide) Approved By FDA For Relapsed And Refractory Multiple Myeloma". The Myeloma Beacon. Retrieved 2013-08-10 ... "Pomalidomide Approved In Europe For Relapsed And Refractory Multiple Myeloma". The Myeloma Beacon. Retrieved 2013-08-10. ... Around that time, the wife of a man who was dying of multiple myeloma and whom standard treatments had failed, called Folkman ... Thalidomide is used as a first-line treatment in multiple myeloma in combination with dexamethasone or with melphalan and ...
... multiple myeloma; or trauma. A normal thoracic spine extends from the 1st thoracic to the 12th thoracic vertebra and should ...
Multiple myeloma is a type of cancer involving malignant plasma cells, called myeloma cells, within the bone marrow. Multiple ... In addition, the efficacy of OPG in bone marrow is impeded with multiple myeloma by excessive binding to syndecan-1. OPG binds ... The reduced OPG in multiple myeloma is caused by suppression of both constitutive OPG transcription and the OPG inducing ... ISBN 978-3-319-42326-5. Palumbo A, Anderson K (March 2011). "Multiple myeloma". The New England Journal of Medicine. 364 (11): ...
... a 68 percent higher risk of multiple myeloma, and double the risk of ALS. On July 18, 2012, the US Senate passed a bill, called ... multiple myeloma; myleodysplasic syndromes; renal toxicity; hepatic steatosis; female infertility; miscarriage; scleroderma; or ... for Disease Control and Prevention found that the contaminated water at Lejeune significantly increased the risk of multiple ...
... multiple myeloma; and bladder cancer. Numerous other cancers were determined to have inadequate or insufficient evidence of ... multiple myeloma, type II diabetes mellitus, Hodgkin's disease, non-Hodgkin's lymphoma, soft tissue sarcoma, chloracne, ... Nguyen Viet Nhan, children in the areas where Agent Orange was used have been affected and have multiple health problems, ... MS2170022626 (PDF) (Report). Archived (PDF) from the original on May 4, 2017.CS1 maint: multiple names: authors list (link) " ...
Expertscape ranks its programs in aplastic anemia and multiple myeloma as best in the world. It has been also ranked the fourth ... Dana-Farber is a member of the Multiple Myeloma Research Consortium. In addition to being a principal teaching affiliate of ... "Expertscape: Multiple Myeloma, February 2014". expertscape.com. February 2014. Retrieved 2014-02-18. "Best Hospitals 2012 ...
ISBN 978-0-8032-7070-1. Morse, Dan F.; Dailey, R. C.; Bunn, Jennings (1974). "Prehistoric multiple myeloma". Bull N Y Acad Med ... possessed markings on her bones which suggested to investigators that she suffered from multiple myeloma. Bohannon excavated ...
Gould, SJ, The Median Isn't the Message, retrieved 1 November 2014 "Multiple Myeloma Prognosis". Multiple Myeloma Prognosis. ... also use to indicator multiple myeloma survive rate. Studies have found that most doctors are overly optimistic when making a ...
"David L. Lucchino - Multiple Myeloma Research Foundation". Multiple Myeloma Research Foundation. 2014-09-09. Retrieved 2018-02- ... In 2013, Lucchino joined the board of the Multiple Myeloma Research Foundation. He is a former member of the Board of Governors ...
He is best known for describing multiple myeloma, a hematological malignancy, which is called "Kahler's disease" in his honor ... Symptomatology of multiple myeloma). Whonamedit biography v t e. ...
She is a supporter of the Multiple Myeloma Research Foundation, of which she is an honorary board member. "About Bonnie Hunt ( ... Multiple Myeloma Research Foundation. Archived from the original on July 15, 2010. Retrieved August 12, 2010. "Sneak peek: ' ...
van de Donk N, Richardson PG, Malavasi F (2018). "CD38 antibodies in multiple myeloma: back to the future". Blood. 131 (1): 13- ... Daratumumab (Darzalex) which targets CD38 has been used in treating multiple myeloma. The use of Daratumumab can interfere with ... Xia C, Ribeiro M, Scott S, Lonial S (October 2016). "Daratumumab: monoclonal antibody therapy to treat multiple myeloma". Drugs ... Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS (2019). "Daratumumab in multiple myeloma". Cancer. 125 (14): 2364-2382. doi: ...
"Honorary Board". Multiple Myeloma Research Foundation. Retrieved February 15, 2008. AP (October 16, 2012). "Olympic figure ... Jude's Children's Hospital and the Multiple Myeloma Research Foundation, of which he is an honorary board member. In 2012, ...
"Honorary Board". Multiple Myeloma Research Foundation. Archived from the original on April 16, 2008. Retrieved October 14, 2008 ... Along with Bob Costas, he supports the Multiple Myeloma Research Foundation as an honorary board member. Olbermann's father, ...
CS1 maint: discouraged parameter (link) "Kenneth Anderson, MD - Multiple Myeloma Research Foundation". Multiple Myeloma ... He continued his medical career at Dana-Farber as a physician and researcher with a special interest in multiple myeloma. ... Anderson sits on the board of directors for the Multiple Myeloma Research Foundation and chairs the organization's scientific ... He directs the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute and is ...
Rock, Hawkman), multiple myeloma. Jakov Labura, 74, Croatian Olympic rower. Frank Martin, 73, American defense attorney and ... Retrieved 2012-08-22.CS1 maint: multiple names: authors list (link) "CE saddened by death of Sir John J. Swaine". The ... Retrieved 2012-08-24.CS1 maint: multiple names: authors list (link) "'Greatest' actor Maureen Toal dies at 82". IrishTimes.com ... Retrieved 8 August 2012.CS1 maint: multiple names: authors list (link) Munatones, Steve. "Croatian Olympian Swimmer Veljko ...
In 2017, Lipman was given the Multiple Myeloma Research Foundation's "Spirit of Hope Award" for his contributions to that ... "Tony Bennett to Perform at the Multiple Myeloma Research Foundation (MMRF) Annual Fall Gala to Benefit Groundbreaking Cancer ... Multiple Myeloma Research Foundation. 16 August 2017. Retrieved 6 March 2019. Greer, Carlos (23 October 2018). "Denise Rich's ...
In 1998 thalidomide was approved by the U.S. Food and Drug Administration (FDA) for use in newly diagnosed multiple myeloma (MM ... This is believed to be a main component of the mechanism in vivo by which thalidomide inhibits multiple myeloma. Additionally, ... Armoiry, X.; Aulagner, G.; Facon, T. (1 June 2008). "Lenalidomide in the treatment of multiple myeloma: a review". Journal of ... Cancer Multiple myeloma Drug design Thalidomide Lenalidomide Pomalidomide Apremilast Organic chemistry Health crisis ...
Among other honors, Lipman also received the Multiple Myeloma Research Foundation's "Spirit of Hope Award" in 2017 and was one ... CS1 maint: discouraged parameter (link) "Tony Bennett to Perform at the Multiple Myeloma Research Foundation (MMRF) Annual Fall ... Multiple Myeloma Research Foundation. 16 August 2017. Retrieved 21 December 2018. CS1 maint: discouraged parameter (link) " ...
"The Multiple Myeloma Research Foundation Congratulates and Supports Senator Kay Bailey Hutchsion for Her Commitment to Blood ... Hutchinson's brother has had multiple myeloma and she worked for several years to pass legislation of this type. The bill came ... and multiple myeloma. The bill was introduced as S. 1094 by Senator Kay Bailey Hutchison of Texas in June 2001. ... Multiple Myeloma Research Foundation. March 24, 2004. Feeney, Mark (May 28, 2001). "John Joseph Moakley dies at age 74". The ...
Plasmacytoma, multiple myeloma, Waldenström macroglobulinemia and plasma cell leukemia are malignant neoplasms ("cancer") of ... Frigyesi I (Jan 2014). "Robust isolation of malignant plasma cells in multiple myeloma". Blood. 123 (9): 1336-40. doi:10.1182/ ... It is also expressed on malignant plasma cells in multiple myeloma. Compared with CD138, which disappears rapidly ex vivo, the ... Multiple myeloma is frequently identified because malignant plasma cells continue producing an antibody, which can be detected ...
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. Journal of Hematology & Oncology. ... Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. December 2011, 306 (23): 2594-605. PMC ... Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis. Immunology Letters. March 2017 ...
It is most often performed for patients with certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia. ... Many recipients of HSCTs are multiple myeloma[10] or leukemia patients[11] who would not benefit from prolonged treatment with ... Multiple sclerosis[edit]. Since McAllister's 1997 report on a patient with multiple sclerosis (MS) who received a bone marrow ... and in some cases multiple myeloma. However, it is less effective in rapidly growing acute leukemias.[38] ...
Gahrton G, Björkstrand B (2000). "Progress in haematopoietic stem cell transplantation for multiple myeloma". J Intern Med 248 ...
... multiple myeloma) and metabolic diseases (diabetes, cystinosis). Structural abnormalities of the kidneys are identified with ...
Multiple myeloma. *Myelofibrosis. N. *Nasopharyngeal carcinoma. *Neuroblastoma. *Neuroendocrine tumor. *Non-Hodgkin lymphoma ...
Mantle cell lymphoma/Multiple myeloma t(11 CCND1:14 IGH). *Anaplastic large-cell lymphoma t(2 ALK;5 NPM1) ...
... multiple myeloma, enteroviral infections, malaria, muscular dystrophy, leukemoid reaction secondary to metastases to the bone ...
Bortezomib is used in the treatment of multiple myeloma.[103] Notably, multiple myeloma has been observed to result in ... "Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma". Blood. 109 (5): 2100-5. ... a proteasome inhibitor used in chemotherapy that is particularly effective against multiple myeloma ... Each end of the core particle associates with a 19S regulatory subunit that contains multiple ATPase active sites and ubiquitin ...
"Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability". PLoS ONE 10 (3): ...
Johansson SG, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin" Immunology 1967; 13:381-94. ... "Incidence and prevalence of multiple allergic disorders recorded in a national primary care database". Journal of the Royal ...
Multiple myeloma can be treated with daratumumab (Darzalex) monoclonal antibody.[6] Studies with in vitro materials and patient ... a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma". J Hematol Oncol. 9 (1): 51. doi:10.1186/ ... induces killing of multiple myeloma and other hematological tumors". J Immunol. 186 (3): 1840-8. doi:10.4049/jimmunol.1003032. ...
Multiple myeloma[edit]. Targets: M-protein levels in blood, patient-specific assays for immunoglobulin and T cell receptor ... Uses: M-protein level in the blood is standard of care and is used for almost all patients with multiple myeloma. Patient- ...
CS1 maint: Multiple names: authors list (link) *^ Chang TW, Wu PC, Hsu CL, Hung AF (2007). Anti-IgE antibodies for the ... Johansson SG, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 1967; 13:381-94. ...
Mantle cell lymphoma/Multiple myeloma t(11 CCND1:14 IGH). *Anaplastic large-cell lymphoma t(2 ALK;5 NPM1) ...
Mantle cell lymphoma/Multiple myeloma t(11 CCND1:14 IGH). *Anaplastic large-cell lymphoma t(2 ALK;5 NPM1) ... She discovered Jacobsen syndrome in a family where multiple people had the disorder. She discovered that the affected children ...
... and multiple myeloma) with use of hair color.[22][23] More specifically, prolonged use of permanent dark hair dyes can double a ... This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to ... The dyes showed high buildup on hair and gave an intense blue color, which was stable to multiple washes.[30] ...
Leukemia, lymphoma and multiple myeloma, 1950-1987". Radiation Research. 137 (2 Suppl): S68-97. Bibcode:1994RadR..137S..68P. ... Hybridomas developed from mouse spleen cells fused to a myeloma cell line can be developed as a source for the cDNA encoding ... In general, cytotoxic chemotherapy for ALL combines multiple antileukemic drugs tailored to each person. Chemotherapy for ALL ... Start CNS prophylaxis and administer intrathecal chemotherapy via Ommaya reservoir or multiple lumbar punctures ...
Lacy, MQ; Tefferi, A (April 2011). "Pomalidomide therapy for multiple myeloma and myelofibrosis: an update". Leukemia & ... multiple subcapsular infarcts often occur in the spleen, meaning that due to interrupted oxygen supply to the spleen partial or ...
Malignancy: Monoclonal gammopathies (multiple myeloma and Waldenström's macroglobulinemia), Hodgkin disease, malignant ... An unusual case involving multiple organs". Acta Pathol. JPN. 30 (1): 109-20. doi:10.1111/j.1440-1827.1980.tb01308.x. PMID ... Peliosis hepatis is an uncommon vascular condition characterised by multiple, randomly distributed, blood-filled cavities ...
Abnormal bands (spikes) are seen in monoclonal gammopathy of undetermined significance and multiple myeloma, and are useful in ... in multiple myeloma) usually appear in this band. Normal present medical procedure involves determination of numerous proteins ...
In breast, prostate or lung cancer, multiple myeloma and some other cancers, sudden onset limb or back pain may indicate ... and about 20 percent of cases involve multiple sites of compression. The nature of the pain depends on the location of the ...
... and multiple myeloma with AstraZeneca receiving $450 million. The second of two-deals is an agreement to study a combination ... "Eolas and AstraZeneca Agree to Develop Orexin-1 Receptor Antagonist for Multiple Indications". GEN.. ...
Real Living with Multiple Sclerosis (página oficial). *Renal and Urology News (Renalandurologynews.com) ... Clinical Lymphoma & Myeloma. *Clinical Ovarian Cancer. *Clinical Dysmorphology (página oficial). *Clinical Journal of Sports ...
As thalidomide is used today as a treatment for multiple myeloma and leprosy, several births of affected children were ... When multiple effects occur in a specified order, it is known as a sequence. When the order is not known, it is a syndrome. ... For 20-25% of anomalies there seems to be a "multifactorial" cause, meaning a complex interaction of multiple minor genetic ... Genetic disorders may be grouped into single-gene defects, multiple-gene disorders, or chromosomal defects. Single-gene defects ...
Multiple copies of the V, D and J gene segments exist, and are tandemly arranged in the genomes of mammals. In the bone marrow ... Chemical similarities to polypetide chains of myeloma globulins and normal gamma-globulins". J. Exp. Med. 116 (2): 207-227. doi ... Multiple attempts have been made to improve both the way that researchers validate antibodies[77][78] and ways in which they ... Targeted monoclonal antibody therapy is employed to treat diseases such as rheumatoid arthritis,[59] multiple sclerosis,[60] ...
... multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma.[4] As an immune ... non-Hodgkin lymphoma and multiple myeloma, occurred in 5 of 119 rheumatoid arthritis patients within the first decade after ... in medical research to produce an animal model for Type 1 diabetes in a large dose as well as Type 2 diabetes with multiple low ...
The partners will perform genomic sequencing on multiple myeloma patients in order to generate data that can help guide ... Multiple Myeloma Research Foundation, UM Form Multiple Myeloma Sequencing Initiative. Aug 05, 2016 ... NEW YORK (GenomeWeb) - The Multiple Myeloma Research Foundation (MMRF) and the University of Michigan announced today that they ... have partnered to provide multiple myeloma patients with access to their genomic information to help guide their treatments. ...
Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood ... "International Myeloma Working Group (IMWG) Criteria for the Diagnosis of Multiple Myeloma". International Myeloma Working Group ... In dogs, multiple myeloma accounts for around 8% of all haemopoietic tumors. Multiple myeloma occurs in older dogs, and is not ... MGUS transforms to multiple myeloma at the rate of 1% to 2% per year, and almost all cases of multiple myeloma are preceded by ...
We searched Medline and the Cochrane collaboration, using the terms "myeloma" and "multiple myeloma". Wherever possible, we ... Multiple myeloma is the second most common (10-15% of all) haematological cancer.1 It is responsible for 15-20% of deaths from ... What is myeloma and who gets it?. In myeloma, neoplastic plasma cells accumulate in the bone marrow (fig 1⇓) and produce a ... Multiple myeloma. BMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f3863 (Published 26 June 2013) Cite this as: BMJ 2013;346: ...
Multiple myeloma is a cancer that develops in the bone marrow , the spongy tissue found in the center of most bones. Explore ... medlineplus.gov/genetics/condition/multiple-myeloma/ Multiple myeloma. ... Multiple myeloma is a cancer that develops in the bone marrow. , the spongy tissue found in the center of most bones. The bone ... Multiple myeloma is considered a rare cancer; it accounts for about 10 percent of cancers of the blood and blood-forming ...
Description Multiple myeloma, also known as plasma cell myeloma, is the second-most common cancer of the blood. ... Definition Multiple myeloma [2] is a cancer in which antibody-producing plasma cells grow in an uncontrolled and invasive ( ... Multiple Myeloma. Definition. Multiple myeloma is a cancer in which plasma cells in the blood grow in an uncontrolled and ... Multiple Myeloma. Definition. Multiple myeloma is a cancer in which antibody-producing plasma cells grow in an uncontrolled and ...
... but not all multiple myeloma cases are the same. Learn more about the types of multiple myeloma and how they differ. ... Multiple myeloma is the second most common type of blood cancer, ... "Multiple myeloma.". Myeloma Crowd: "Types of Multiple Myeloma." ... Types of Multiple Myeloma. Articles OnMultiple Myeloma Types & Stages. Multiple Myeloma Types & Stages Multiple Myeloma Types ... Smoldering Multiple Myeloma If you have multiple myeloma, cancerous plasma cells divide and grow inside your bone marrow. ...
... Radiation therapy uses high-energy rays or particles to kill cancer cells. Radiation ... The type of radiation therapy most often used to treat multiple myeloma or solitary plasmacytoma is called external beam ... Rajkumar SV, Dispenzieri A. Multiple myeloma and related disorders. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, ... If myeloma severely weakens the vertebral (back) bones, these bones can collapse and put pressure on the spinal cord and spinal ...
Multiple myeloma accounts for around 1% of all cancers worldwide and for about 2% of cancer-related deaths. The most common age ... Multiple myeloma affects thousands of people worldwide and is the second most common cancer of the blood only to non-Hodgkins ... Multiple Myeloma Epidemiology. News-Medical. 22 June 2021. ,https://www.news-medical.net/health/Multiple-Myeloma-Epidemiology. ... Multiple Myeloma Epidemiology. News-Medical, viewed 22 June 2021, https://www.news-medical.net/health/Multiple-Myeloma- ...
... serious symptoms may manifest and affect multiple sites in the body which is why the condition is named multiple myeloma. ... The symptoms of multiple myeloma are not usually evident in the early stages of disease, which is often only detected or ... Bone pain - In multiple myeloma, abnormal plasma cells (myeloma cells) are produced in high quantities which produce abnormal ... Multiple Myeloma Symptoms. News-Medical. 25 September 2021. ,https://www.news-medical.net/health/Multiple-Myeloma-Symptoms. ...
Learn about multiple myeloma and Novartis Oncologys commitment to research & development for patients living with this rare ... About multiple myeloma. Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell in the bone marrow ... When myeloma cells collect in several sites, it is called multiple myeloma.1 While it is a rare cancer, it is the second most ... Multiple Myeloma Treatment Overview. Multiple Myeloma Research Foundation. Available at: http://www.themmrf.org/assets/living- ...
Anthropometry and multiple myeloma.. Bosetti C, Negri E, Gallus S, Dal Maso L, Franceschi S, La Vecchia C. ...
Multiple myeloma is a type of blood cancer. Read about the basics of the disease, including what causes it, how it makes you ... "Learn the Basics About Multiple Myeloma," "Risk Factors for Multiple Myeloma," "Multiple Myeloma Symptoms," "Multiple Myeloma ... "Diagnosing Multiple Myeloma from Test Results," "How Is Multiple Myeloma Staged?" "CAR T-cell Therapy for Multiple Myeloma." ... "What Are the Risk Factors for Multiple Myeloma?" "Signs and Symptoms of Multiple Myeloma," "Staging Multiple Myeloma," " ...
... and signs of multiple myeloma and the medications used in treatment. Common symptoms and signs include bone pain, fatigue, and ... Main Article on Multiple Myeloma Symptoms and Signs. * Multiple Myeloma. Multiple myeloma is a form of cancer that develops in ... Multiple Myeloma Quiz. Multiple myeloma is a form of cancer. Take this quiz common signs and symptoms of multiple myeloma and ... Multiple myeloma is also referred to as myeloma.. Multiple myeloma causes a host of organ problems and symptoms. Common ...
Although some patients with multiple myeloma have no symptoms at all, the following are the most common symptoms of this ... Signs and Symptoms of Multiple Myeloma. Some patients with multiple myeloma have no symptoms at all. Others can have common ... Patients with amyloidosis (discussed in What Is Multiple Myeloma?) can have some of the same problems as patients with myeloma ... Shortages of red blood cells, white blood cells, and blood platelets are common in multiple myeloma and might lead to other ...
Multiple myeloma, is a rare cancer of the plasma cells that causes tumors in the bones. Learn more about what it is and how it ... Risk factors for multiple myeloma. (n.d.). Retrieved from https://www.themmrf.org/multiple-myeloma/multiple-myeloma-causes/ ... www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-key-statistics. I have multiple myeloma. What should I eat ... Multiple myeloma is a cancer of the blood plasma. Multiple myeloma is a type of cancer. Cancer starts when the structure of the ...
... LIST. Name. Occupation. Birth. Death. Known for. Tom Brokaw. Journalist. 6-Feb-1940. Former ...
Thirteen years after his first multiple myeloma diagnosis, Stan reflects on the choices he made along the way. Heres his ... How Multiple Myeloma Affects the Body Multiple myeloma can cause problems ranging from bone pain and bone loss to kidney damage ... Understanding Multiple Myeloma Multiple myeloma, often called bone marrow cancer, is an incurable illness, but treatment that ... On top of this, his specialty wasnt multiple myeloma. You dont want to go to a general oncologist with multiple myeloma. You ...
Multiple myeloma (MM) is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of ... Multiple Myeloma) and Multiple Myeloma What to Read Next on Medscape. Related Conditions and Diseases. * Multiple Myeloma ... Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015 Jan. 100(1): ... International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease. J Clin Oncol. ...
Multiple myeloma may be a singularly promising target for cellular immunotherapies, according to data presented at the most ... Cite this: Cellular Immunotherapy for Multiple Myeloma Advancing Rapidly - Medscape - Jan 30, 2017. ... Myeloma Patients Could Self-administer Bortezomib at Home * U.S. Court Rejects Alvogens Patent Challenge for Celgenes Cancer ... In the case of MILs, the T cells targeted for harvesting are myeloma specific. Various strategies have been used to enhance ex ...
Email: [email protected]myeloma.ca ©2020 Myeloma Canada - All Rights Reserved. Charitable Registration Number: 862533296RR0001 ... Myeloma Canada 1255 TransCanada, Suite 160 Dorval, QC H9P 2V4 Tel: 514 421-2242 , Toll-free: 1 888 798-5771 ... If you donate and have not already registered, you will receive periodic updates and communications from Myeloma Canada , My ...
Our multiple myeloma patient support group provides a safe space to connect with others coping with multiple myeloma and is led ... Connect with others in our free, 15-week online support group for people diagnosed with multiple myeloma who are currently ...
If you have multiple myeloma, the side effects of chemotherapy can cause you to lose your appetite. Learn how to maintain a ... Multiple myeloma and nutrition. Multiple myeloma is a type of cancer that affects plasma cells, which are a part of your immune ... More in Shedding Light on Multiple Myeloma. *. To Others Living with Multiple Myeloma, Youre Not Alone ... Ask the Expert: Targeted Therapy for Multiple Myeloma. A doctor answers questions about targeted therapy for multiple myeloma. ...
Information and resources about multiple myeloma from CancerCare. ... Multiple Myeloma. *Caregiving for a Loved One with Multiple ... Multiple Myeloma. *. Q.. I am 66 years old, was diagnosed with multiple myeloma 2005, and have been in remission for 40 months ... Multiple Myeloma. CancerCare provides free, professional support services for people affected by multiple myeloma, as well as ... Additional resources include International Myeloma Foundation, Leukemia & Lymphoma Society and Multiple Myeloma Research ...
We report three cases of IgG kappa multiple myeloma with pseudohyperphosphatemia. The patients serum calcium levels were ... Kyle RA (1975) Multiple myeloma: review of 869 cases. Mayo Clin Proc 50:29-40Google Scholar ... Jarchowsky I, Beitner H, Plavnick L (1991) Spurious hyperphosphatemia in multiple myeloma. Harefuah 121:515-516Google Scholar ... Savage D, Garrett TJ (1986) Multiple myeloma masquerading as metastatic breast cancer. Cancer 57:923-924Google Scholar ...
All About Multiple Myeloma Overview of the diagnosis and treatment of multiple myeloma. Multiple myeloma is a cancer of the ... Multiple myeloma in cats M Protein in multiple myeloma Cord Blood Donation Environmental Link to Canine Cancers Treatment For ... Multiple Myeloma: The Basics This article provides basic information about Multiple Myeloma, its diagnosis and treatment. ... Including Multiple Myeloma) Treatment (PDQ®) (Health professionals) Plasma Cell Neoplasms (Including Multiple Myeloma) ...
... among four new variants that they linked to multiple myeloma. ... Multiple myeloma: link to gene involved in aging. Published ... "Multiple myeloma: link to gene involved in aging." Medical News Today. MediLexicon, Intl., 19 Aug. 2013. Web.. 22 Mar. 2018. , ... Whiteman, H. (2013, August 19). "Multiple myeloma: link to gene involved in aging." Medical News Today. Retrieved from. https ... Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk, Daniel Chubb, Niels Weinhold, Peter ...
... especially for relapsed multiple myeloma, herald an exciting new era in the management of this disease, experts say. ... "We have to recognize that there are probably many diseases that are buried under the name multiple myeloma. As time goes on, ... The preferred regimens for previously treated multiple myeloma now are as follows, all with category 1 evidence:. *. bortezomib ... In the area of previously treated multiple myeloma, there were several changes to the updated guidelines, including agents in ...
Mark T.M., Pearse R.N. (2008) Pathophysiology of Bone Disease in Multiple Myeloma. In: Lonial S. (eds) Myeloma Therapy. ... Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group J ... International staging system for multiple myeloma. J Clin Oncol 2005; 23(15):3412-3420.PubMedCrossRefGoogle Scholar ... Multiple Myeloma Bone Marrow Stromal Cell Bone Destruction Adenomatous Polyposis Coli Gene Bone Marrow Plasma These keywords ...
Multiple myeloma is a type of cancer that develops in your bone marrow, causing the antibodies in your blood to stop working ... Diagnosing multiple myeloma can be tricky for your doctor, as the... ... Determine if you are at risk for multiple myeloma. Some people have a higher risk of developing multiple myeloma than others. ... Diagnose-Multiple-Myeloma-Step-1.jpg\/v4-460px-Diagnose-Multiple-Myeloma-Step-1.jpg","bigUrl":"\/images\/thumb\/c\/c0\/Diagnose ...
  • If you have multiple myeloma, the side effects of chemotherapy may cause you to lose your appetite and skip meals. (healthline.com)
  • The type of radiation therapy most often used to treat multiple myeloma or solitary plasmacytoma is called external beam radiation therapy. (cancer.org)
  • There are two types of stem cell transplants to treat multiple myeloma. (wikipedia.org)
  • How Does Revlimid Treat Multiple Myeloma? (livestrong.com)
  • These myeloma cells may form tumors called plasmacytomas. (encyclopedia.com)
  • As they collect in the different bones, they can cause multiple tumors. (medicalnewstoday.com)
  • If myeloma causes bone pain due to fractures or tumors, patients who have not yet been diagnosed and advised often take over the counter pain medications of the NSAID (nonsteroidal anti-inflammatory drug) class like ibuprofen, and these medications can also be the cause of kidney problems since myeloma kidneys are more susceptible to their side effects on the kidneys. (moffitt.org)
  • The mechanisms are stimulation of osteoclasts as mentioned above or the development of myeloma tumors in bones. (moffitt.org)
  • Abnormal plasma cells, called myeloma cells, grow uncontrolled in a manner that produces bulky tumors in the body's bone marrow. (nurse.com)
  • Activating mutations of NRAS and KRAS are each present in about 15% of multiple myeloma tumors. (hindawi.com)
  • Jonathan Keats, Ph.D., head of TGen's Multiple Myeloma Research Laboratory, said: "This study, which leverages data generated at TGen as part of the Multiple Myeloma Genomics Initiative, shows how mutations acquired by multiple myeloma tumors can make a tumor resistant to specific therapies and highlights the importance of TGen's precision medicine approaches. (redorbit.com)
  • Multiple myeloma is characterized by the presence of multiple tumors. (thirdage.com)
  • Multiple myeloma is characterized by the presence of multiple malignant plasma cell tumors known as plasmacytomas. (thirdage.com)
  • These myeloma cells multiply randomly and without order, forming collections of cells called tumors that accumulate most commonly in the bone marrow and on the surfaces of different bones in the body. (drugs.com)
  • In this cancer , plasma cells (a type of white blood cell ) accumulate in the bone marrow, giving rise to tumors in multiple bones of the body. (rxlist.com)
  • It is called multiple myeloma because it is characterized by plasma cell tumors in bones in multiple parts of the body. (va.gov)
  • In tackling the dilemma of treatment failure, the researchers identified a cancer cell maturation hierarchy within multiple myeloma tumors and demonstrated the critical role of myeloma cell maturation in proteasome inhibitor sensitivity. (medindia.net)
  • W. Michael Kuehl, M.D., chief of the Molecular Pathogenesis of Myeloma Section of the CCR Genetics Branch and a co-director of the study, stated that "Our studies suggest that activation of the NF-kappaB pathway by signals from normal bone marrow cells is critical not only for survival of normal plasma cells but also for pre-malignant and malignant myeloma tumors. (nih.gov)
  • The importance of this pathway is highlighted by essential mutations in some myeloma tumors. (nih.gov)
  • Regardless of whether or not there are mutations in this pathway, most myeloma tumors may be sensitive to NF-kappaB inhibitors. (nih.gov)
  • While there is no cure for multiple myeloma, there are FDA-approved treatments to target the cancer and slow down the spread of the disease. (fda.gov)
  • Introducing the IMF's Black Swan Research Initiative® Understanding that the search for a cure for multiple myeloma demands constant innovation, the IMF has launched the Black Swan Research Initiative®, a unique project to develop the first definitive cure for myeloma. (myeloma.org)
  • Our findings reveal a way forward toward a cure for multiple myeloma, which involves targeting both the progenitor cells and the plasma cells at the same time," says Rodger Tiedemann, M.D., a hematologist specializing in multiple myeloma and lymphoma at Princess Margaret. (redorbit.com)
  • WebMD states that currently there is no cure for multiple myeloma and that the treatments move slowly in dealing with the disorder. (reference.com)
  • As of September 2014, there is no known cure for multiple myeloma, according to Mayo Clinic. (reference.com)
  • There's no cure for multiple myeloma. (mdanderson.org)
  • But MGUS doesn't cause other symptoms of myeloma. (webmd.com)
  • In those with MGUS, myeloma or another cancer develops at a rate of 1% per year. (medicinenet.com)
  • In addition we know that a common condition called MGUS predisposes to the development of myeloma. (medicalnewstoday.com)
  • A monoclonal proliferation of PC is also present in other conditions that can be considered as preclinical phases of MM, including monoclonal gammopathy of undetermined significance (MGUS) and asymptomatic or smoldering myeloma (SMM). (hindawi.com)
  • The rate of evolution from these preclinical conditions to an overt myeloma is very low and it has been calculated to be 1% per year for MGUS and 10% per year for SMM. (hindawi.com)
  • However, while both MGUS and SMM lack the clinical features of MM, they harbor the same genetic alterations of symptomatic myeloma [ 4 , 5 ]. (hindawi.com)
  • Besides additional, acquired genetic and epigenetic changes of PC, it is likely that a "permissive" microenvironment plays a significant role in the evolution from MGUS to symptomatic myeloma [ 6 ]. (hindawi.com)
  • Another risk factor for multiple myeloma is a history of monoclonal gammopathy of undetermined significance (MGUS). (healthline.com)
  • However, MGUS can sometimes develop into multiple myeloma over time. (healthline.com)
  • Multiple myeloma almost always starts out as a relatively benign condition called monoclonal gammopathy of undetermined significance (MGUS). (mayoclinic.org)
  • MGUS , like multiple myeloma, is marked by the presence of M proteins - produced by abnormal plasma cells - in your blood. (mayoclinic.org)
  • Those that have been diagnosed with solitary plasmacytoma, or monoclonal gammopathy of uncertain significance (MGUS), are also at risk for developing mutlple myeloma. (reference.com)
  • All myeloma patients started with MGUS, but not all patients with MGUS will develop myeloma," says Dr. Alan Feiner, a hematologist-oncologist at Rocky Mountain Cancer Center in Denver, Colo. "About one third of MGUS patients will eventually develop multiple myeloma, but MGUS usually causes no problems. (healthgrades.com)
  • About 20 to 30% of individuals with MGUS if followed up for a very long time will go on to develop myeloma or some other related disease such as lymphoma . (labtestsonline.org.uk)
  • Some of the tests used to diagnose and/or follow multiple myeloma are used to monitor patients with MGUS. (labtestsonline.org.uk)
  • All of the paraproteins from any one individual are monoclonal (identical) because the myeloma cells are identical clones of a single plasma cell. (encyclopedia.com)
  • In about 75% of multiple myeloma cases, the malignant plasma cells also produce monoclonal light chains, or incomplete Igs. (encyclopedia.com)
  • Two monoclonal antibodies - options for use in relapsed multiple myeloma - are also new in the updated guidelines. (medscape.com)
  • Multiple Myeloma (MM) is a systemic hematologic disease due to uncontrolled proliferation of monoclonal plasma cells (PC) in bone marrow (BM). (hindawi.com)
  • Blood and urine tests for monoclonal proteins - These are the useless antibodies or antibody fragments called light chains that come from the clone of myeloma cells. (moffitt.org)
  • Monoclonal proteins can usually be detected in the blood and/or urine of multiple myeloma patients. (moffitt.org)
  • Because the monoclonal protein is sometimes found in patients who do not have multiple myeloma, further testing will be required if it is identified in order to reach a definitive diagnosis. (moffitt.org)
  • Today, the U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. (fda.gov)
  • Multiple myeloma (MM) is a hematologic malignancy characterized by the accumulation of monoclonal plasma cells in the bone marrow (BM), over 10% by definition [ 1 ]. (hindawi.com)
  • Normally, multiple myeloma begins as a condition called monoclonal gammopa. (reference.com)
  • In multiple myeloma, the plasma cells make an abnormal substance known as a monoclonal protein. (healthgrades.com)
  • But having monoclonal proteins in your blood does not mean you have multiple myeloma. (healthgrades.com)
  • This immunoglobulin may also be called monoclonal immunoglobulin, myeloma protein, or simply M protein. (drugs.com)
  • Multiple myeloma (MM) is characterized by the neoplastic proliferation of plasma cells producing a monoclonal immunoglobulin. (uptodate.com)
  • Sometimes people will produce abnormal amounts of identical copies of the same immunoglobulin (also known as monoclonal gammopathy) but not have any of the symptoms or complications of multiple myeloma. (labtestsonline.org.uk)
  • Multiple myeloma is a monoclonal tumor of plasma cells, and its development is preceded by a premalignant tumor with which it shares genetic abnormalities, including universal dysregulation of the cyclin D/retinoblastoma (cyclin D/RB) pathway. (jci.org)
  • Multiple myeloma (MM) is an age-dependent monoclonal tumor of BM plasma cells (PCs). (jci.org)
  • There are two conditions that can be precursors to multiple myeloma: monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. (mdanderson.org)
  • The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of patients with MM refractory to CD38 MoABs have not been described. (nature.com)
  • In Western industrialized countries, approximately four people in 100,000 develop multiple myeloma. (encyclopedia.com)
  • African Americans are more than twice as likely to develop multiple myeloma than white Americans. (thirdage.com)
  • Veterans who develop multiple myeloma and were exposed to Agent Orange or other herbicides during military service do not have to prove a connection between their disease and service to be eligible to receive VA health care and disability compensation. (va.gov)
  • Are some people more likely to develop multiple myeloma? (mdanderson.org)
  • Multiple myeloma ( MM ), also known as plasma cell myeloma and simply myeloma , is a cancer of plasma cells , a type of white blood cell that normally produces antibodies . (wikipedia.org)
  • [10] Multiple myeloma is diagnosed based on blood or urine tests finding abnormal antibodies, bone marrow biopsy finding cancerous plasma cells, and medical imaging finding bone lesions. (wikipedia.org)
  • Most people with myeloma make antibodies known as immunoglobulins. (webmd.com)
  • It involves M proteins, which are abnormal antibodies made by myeloma cells. (webmd.com)
  • Bone pain - In multiple myeloma, abnormal plasma cells (myeloma cells) are produced in high quantities which produce abnormal antibodies. (news-medical.net)
  • Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell in the bone marrow that produces antibodies and helps fight infection. (novartis.com)
  • Multiple myeloma features abnormal proliferation of plasma cells in the bone marrow, destructive bone lesions, and the production of abnormal proteins, specifically antibodies. (medicinenet.com)
  • Multiple myeloma is a form of cancer that develops in plasma cells, the white blood cells that make antibodies. (medicinenet.com)
  • Multiple myeloma is a type of cancer that develops in your bone marrow, causing the antibodies in your blood to stop working correctly. (wikihow.com)
  • Cancerous plasma cells (= myeloma cells) can grow and multiply, "blindly" produce useless and sometimes incomplete antibodies (called light chains) and release molecules (called cytokines) that can affect healthy cells around them. (moffitt.org)
  • If myeloma produces incomplete antibodies called light chains, they are small enough to be filtered by the kidneys and if they reach high concentrations in the kidneys they can fall out of solution, form casts, and trigger an inflammatory reaction that results in kidney failure. (moffitt.org)
  • If multiple myeloma is suspected in an individual who is experiencing frequent infections, fatigue, anemia, bone pain or has laboratory findings such as low kidney function, high calcium or high total protein (excess useless antibodies released by myeloma increase the total protein value), testing may be recommended. (moffitt.org)
  • Multiple myeloma is cancer that begins in plasma cells (white blood cells that produce antibodies) and may also be referred to as plasma cell myeloma. (fda.gov)
  • The myeloma cells continue trying to produce antibodies, as healthy plasma cells do, but the myeloma cells produce abnormal antibodies that the body can't use. (mayoclinic.org)
  • But myeloma plasma cells make abnormal antibodies. (cigna.com)
  • Multiple myeloma is a bone marrow-based cancer that arises in plasma cells, a type of white blood cells that produce proteins that help the body fight infections (known as antibodies). (patientslikeme.com)
  • CAR T-cells and bispecific antibodies as single agents may offer new hope to patients with myeloma, but they also may provide the opportunity for new combinations with other novel targeted therapies under investigation. (bms.com)
  • The patient's blood is checked for abnormal antibodies produced by myeloma cells. (aaos.org)
  • A 2016 study concluded that stem cell transplant is the preferred treatment of multiple myeloma. (wikipedia.org)
  • In 2016, Myeloma Canada produced two patient submissions to pCODR for daratumumab, in combination with dexamethasone, and one for ixazomib plus lenalidomide (Revlimid®) and dexamethasone. (newswire.ca)
  • According to the American Cancer Society , more than 30,000 people in the United States will be newly diagnosed with multiple myeloma in 2018. (healthline.com)
  • 41 NCCN Guidelines for Patients ® : Multiple Myeloma, 2018 4 Treatment guide Solitary plasmacytoma Follow-up tests After you finish primary treatment, you should have follow-up tests every 3 to 6 months. (nccn.org)
  • The most widely accepted schema for the diagnosis of multiple myeloma (MM) uses particular combinations of laboratory, imaging, and procedure findings as diagnostic criteria. (medscape.com)
  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (medscape.com)
  • Several tests are used to confirm a diagnosis of multiple myeloma, including x-rays, bone scans, a bone biopsy, and a blood test. (aaos.org)
  • 20 NCCN Guidelines for Patients ® : Multiple Myeloma, 2019 2 Testing for myeloma Tissue tests Tissue biopsy If you have a solitary plasmacytoma, a tissue biopsy may be done to remove a sample of the mass for testing. (nccn.org)
  • 21, 2019 (HealthDay News) -- Patients with a form of blood cancer known as multiple myeloma who haven't responded to other therapies might have a new weapon against the disease, researchers say. (thefreedictionary.com)
  • Nonclinical efficacy data presented at the 2019 American Society of Hematology (ASH) Annual Meeting demonstrated that CD38-ARMs are able to kill multiple myeloma cells by antibody-dependent cellular cytotoxicity without depleting CD38-expressing immune cells. (prnewswire.com)
  • Some people with multiple myeloma don't make enough M proteins or light chains for tests to show they have it. (webmd.com)
  • You may have lab tests every 3 to 6 months to check for an increase in M proteins or signs of the organ damage active myeloma can cause. (webmd.com)
  • People with smoldering multiple myeloma have more M proteins in their blood or more myeloma plasma cells in their bone marrow. (webmd.com)
  • Sometimes, the abnormal proteins produced by myeloma cells are toxic to nerves. (cancer.org)
  • These proteins may be caused by multiple myeloma or other conditions. (healthline.com)
  • However, a team of researchers led by Xin-Yan Pei, M.D., Ph.D., and Steven Grant, M.D., recently published the findings of a study in the journal PLoS ONE demonstrating that a novel drug combination both reduces Mcl-1 expression and disrupts its interactions with other proteins to effectively kill multiple myeloma cells. (eurekalert.org)
  • Multiple myeloma is a cancer caused by an overproduction of certain proteins from white blood cells. (va.gov)
  • Some forms of multiple myeloma produce proteins that can be detected with a urine analysis. (aaos.org)
  • Finally, myeloma can cause kidney problems due to overproduction of proteins that deposit in the kidneys by the myeloma cells. (mdanderson.org)
  • The symptoms of multiple myeloma are not usually evident in the early stages of disease, which is often only detected or diagnosed as a result of routine blood and urine tests. (news-medical.net)
  • Generalized symptoms of multiple myeloma include unexplained fatigue, bone pain and weight loss. (news-medical.net)
  • The signs and symptoms of multiple myeloma depend on the stage of the cancer and the general health of the patient. (medicalnewstoday.com)
  • What are the symptoms of multiple myeloma? (healthline.com)
  • The symptoms of multiple myeloma vary depending on the person. (healthline.com)
  • Signs and symptoms of multiple myeloma can vary and, early in the disease, there may be none. (mayoclinic.org)
  • This leads to the development of symptoms of multiple myeloma - kidney damage, bone pain, and fractures due to bone damage. (newsmax.com)
  • Symptoms of multiple myeloma usually don't appear until the disease is more advanced. (drugs.com)
  • NEW YORK (MarketWatch) -- Amgen Inc. shares AMGN, -0.79% climbed 3.5% in premarket trade Monday, after the company said a late-stage trial of a treatment for patients with relapsed multiple myeloma had positive results. (marketwatch.com)
  • Revlimid, manufactured by Celgene, is a derivative of of thalidomide that has extended survival in patients with relapsed multiple myeloma. (livestrong.com)
  • Does lenalidomide plus dexamethasone improve outcome in patients with relapsed multiple myeloma? (nih.gov)
  • Multiple myeloma is the second most common (10-15% of all) haematological cancer. (bmj.com)
  • Although myeloma remains an incurable cancer, survival is improving, and newly diagnosed patients are now projected to live for around five years. (bmj.com)
  • Multiple myeloma is a cancer in which antibody-producing plasma cells grow in an uncontrolled and invasive (malignant) manner. (encyclopedia.com)
  • Multiple myeloma , also known as plasma cell myeloma, is the second-most common cancer of the blood. (encyclopedia.com)
  • Multiple myeloma accounts for approximately 1% of all cancers and 2% of all deaths from cancer. (encyclopedia.com)
  • Multiple myeloma is one of the leading causes of cancer deaths among African Americans . (encyclopedia.com)
  • Multiple myeloma affects thousands of people worldwide and is the second most common cancer of the blood only to non-Hodgkin's lymphoma. (news-medical.net)
  • The American Cancer Society predicted that in 2013, around 22,350 new cases of multiple myeloma would be diagnosed (12,440 in men and 9,910 in women) and around 10,710 deaths would occur (6,070 in men and 4,640 in women). (news-medical.net)
  • 3 After initial therapy, it is common for individuals with multiple myeloma to become less responsive to therapy or eventually experience a relapse, when the cancer returns. (novartis.com)
  • Multiple myeloma is a type of blood cancer. (webmd.com)
  • When your doctor diagnoses multiple myeloma, they'll try to give you an idea of how much the cancer has grown or spread in your body. (webmd.com)
  • There are many myeloma cells, and the cancer has destroyed three or more areas of bone. (webmd.com)
  • Multiple myeloma is a cancer of certain cells of the bone marrow called plasma cells. (medicinenet.com)
  • Multiple myeloma is a form of bone marrow cancer . (medicinenet.com)
  • The American Cancer Society (ACS) estimates the risk of developing multiple myeloma over a lifetime as 1 in 143 or 0.7 percent . (medicalnewstoday.com)
  • It was during my first oncology visit with Dr. York that I received the diagnosis: I had multiple myeloma, a type of blood cancer. (healthgrades.com)
  • Multiple myeloma is a type of cancer that affects plasma cells, which are a part of your immune system. (healthline.com)
  • Cancer Care provides free, professional support services for people affected by multiple myeloma, as well as multiple myeloma treatment information and additional resources. (cancercare.org)
  • Savage D, Garrett TJ (1986) Multiple myeloma masquerading as metastatic breast cancer. (springer.com)
  • Multiple myeloma is a cancer of the blood (hematologic cancer) in which one population of clonal (identical) plasma cells starts to reproduce uncontrollably. (oncolink.org)
  • Scientists from The Institute of Cancer Research in the UK found a genetic variant called TERC among four new variants that they linked to multiple myeloma - a form of cancer that affects immune cells produced in the bone marrow for circulation in the blood. (medicalnewstoday.com)
  • Myeloma is a relatively uncommon cancer according to the American Cancer Society statistics, with a 1 in 149 risk of developing the disease in the US. (medicalnewstoday.com)
  • For the study, the research team analyzed the genetic make-up of 4,692 patients who had myeloma, and compared this with DNA of 10,990 people who did not have the blood cancer. (medicalnewstoday.com)
  • They add that if the link between TERC and myeloma is confirmed, this could lead to new treatments of the blood cancer. (medicalnewstoday.com)
  • Richard Houlston, professor of molecular and population genetics at The Institute of Cancer Research ( ICR ), explains: "Our study has taken an important step forward in understanding the genetics of myeloma, and suggested an intriguing potential link with a gene that acts as a cell's internal timer. (medicalnewstoday.com)
  • HOLLYWOOD, Florida - In the latest version of the multiple myeloma guidelines issued by the National Comprehensive Cancer Network (NCCN), three major changes reflect the rapid advances in the diagnosis and treatment of this disease. (medscape.com)
  • The updated guidelines were presented here at the NCCN 21st Annual Conference by Kenneth C. Anderson, MD, Kraft Family Professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute in Boston, and chair of the NCCN Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström's Macroglobulinemia Panel. (medscape.com)
  • If the cancer has spread, see Guide 1 on page 16 for recommended testing to assess the severity of multiple myeloma and its symptoms. (nccn.org)
  • Next steps  If tests show the cancer has spread, the next treatment options depend on the severity of myeloma and its symptoms. (nccn.org)
  • According to Stanford University, multiple myeloma is rare, accounting for only 1 percent of all cancer cases in the United States. (healthline.com)
  • Among the many frustrating things about the blood cancer known as multiple myeloma is the fact that it's hard to predict who will get it. (healthcentral.com)
  • But multiple myeloma cancer cells are often found to have an extra chromosome or may be missing a part of one chromosome. (healthcentral.com)
  • Reuters) - Amgen Inc's Kyprolis drug failed to extend survival compared to standard care in a trial involving patients with advanced multiple myeloma, a type of blood cancer that develops in the bone marrow. (yahoo.com)
  • Multiple myeloma is a cancer of antibody producing cells, called plasma cells, which are located in the bone marrow. (moffitt.org)
  • Multiple myeloma is a hematological cancer that involves a type of white blood cell called a plasma cell. (nurse.com)
  • According to the American Cancer Society, in 2015 about 26,850 people will be diagnosed with multiple myeloma (14,090 men and 12,760 women). (nurse.com)
  • At Moffitt Cancer Center, we perform extensive research and have an active multiple myeloma clinical trials program. (moffitt.org)
  • Each year, more than 25,000 Americans are diagnosed with multiple myeloma, a form of blood cancer that often develops resistance to therapies. (eurekalert.org)
  • Not only was the combination therapy effective against multiple myeloma cells, it notably did not harm normal bone marrow cells, raising the possibility of therapeutic selectivity," says Grant, the study's lead investigator and Shirley Carter Olsson and Sture Gordon Olsson Chair in Cancer Research, associate director for translational research and program co-leader of Developmental Therapeutics at VCU Massey Cancer Center. (eurekalert.org)
  • Researchers have discovered why multiple myeloma, a difficult to cure cancer of the bone marrow, frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. (redorbit.com)
  • The research team initially analyzed 7,500 genes in multiple myeloma cells to identify genes which when suppressed made cancer cells resistant to a common class of drugs called proteasome inhibitors such as bortezomib or carfilzomib. (redorbit.com)
  • According to the American Cancer Society, there are three stages of multiple myeloma. (reference.com)
  • The survival rates for multiple myeloma are 62, 44 and 29 months for stages one, two and three, respectively, according to Cancer.org. (reference.com)
  • As explained in the Introduction , a person with a small amount of M protein in their blood has a 1% to 2% chance of developing myeloma, lymphoma , or another blood-related cancer called Waldenstrom's macroglobulinemia per year (see the Stages section for more information). (cancer.net)
  • Multiple myeloma is a form of cancer that is caused by the malignant and abnormal growth of plasma cells. (thirdage.com)
  • The most comprehensive genetic study to date of the blood cancer multiple myeloma has revealed that the genetic landscape of the disease may be more complicated than previously thought. (eurekalert.org)
  • What this new work shows us is that when we treat an individual patient with multiple myeloma, it's possible that we're not just looking at one disease, but at many - in the same person, there could be cancer cells with different genetic make-ups," said co-senior author Todd Golub, the Broad Institute's Chief Scientific Officer and Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute. (eurekalert.org)
  • In a detailed study of samples from more than 200 multiple myeloma patients, Golub and colleagues identified frequent mutations in several key genes known to play an important role in cancer including KRAS, NRAS, and BRAF. (eurekalert.org)
  • Even though nearly 33,000 Americans are diagnosed with multiple myeloma each year, many people are not familiar with this form of blood cancer. (healthgrades.com)
  • Here's what three multiple myeloma specialists want you to know about this uncommon blood cancer . (healthgrades.com)
  • Multiple myeloma is not a bone cancer, but much of the damage it causes is related to the bones in some way," says Dr. Feiner. (healthgrades.com)
  • In laboratory experiments, multiple myeloma patients had increased levels of sclerostin, which correlated with tumor burden, Homare Eda, MD, PhD, research fellow in cancer at Harvard Medical School in Boston, told MedPage Today . (medpagetoday.com)
  • David Vesole, MD, PhD, co-chief of the myeloma division at John Theurer Cancer Center at Hackensack University Hospital, New Jersey, noted that scientists have been looking for various targets in multiple myeloma and have had success in finding substances in the laboratory that seem like promising targets. (medpagetoday.com)
  • They determined that blood plasma sclerostin levels were higher in the multiple myeloma patients when compared to three leukemia patients, 40 gastric cancer patients, and four healthy volunteers. (medpagetoday.com)
  • Multiple myeloma is a type of cancer that forms in plasma cells (also called mature B-lymphocytes), which are a type of white blood cell that is made in the bone marrow. (drugs.com)
  • One cancer being tested is multiple myeloma, a disease that affects blood cells. (bms.com)
  • So a new potentially successful bispecific antibody therapy might, for example, have one arm that binds to myeloma cells via BCMA and another that binds to T-cells, one of the immune system's top cancer assassins. (bms.com)
  • If there's one disease that most shows the effects of recent improvements in cancer treatment, it's multiple myeloma. (harvard.edu)
  • Multiple myeloma treatment is a very active area of cancer research. (cancer.net)
  • The reason, explains research published online today in Cancer Cell , is intrinsic resistance found in immature progenitor cells that are the root cause of the disease - and relapse - says principal investigator Dr. Rodger Tiedemann, a hematologist specializing in multiple myeloma and lymphoma at the Princess Margaret, University Health Network (UHN). (medindia.net)
  • Multiple myeloma is an uncommon cancer. (cancervic.org.au)
  • Multiple myeloma (also known as "myeloma") is the most common primary bone cancer. (aaos.org)
  • Multiple myeloma is named for the "clock face" appearance of the cancer cells when seen under a microscope. (aaos.org)
  • Research investigators have identified molecular changes in multiple myeloma cells that activate an important biological pathway associated with cell growth and survival, thereby revealing potential new targets for drugs to treat this cancer. (nih.gov)
  • The researchers, led by a team from the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that malignant cells in multiple myeloma frequently harbor mutations that activate what is called the NF-kappaB signaling pathway, which plays a key role in promoting cell growth and preventing programmed cell death. (nih.gov)
  • This is one of the largest collaborative translational cancer research efforts of its kind," said John Shaughnessy, Jr., Ph.D., director of the Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics and chief of Basic Sciences at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences, Little Rock, Ark. (nih.gov)
  • Aflibercept may be able to carry cancer-killing substances directly to multiple myeloma cells. (clinicaltrials.gov)
  • It may also stop the growth of multiple myeloma by blocking blood flow to the cancer. (clinicaltrials.gov)
  • MONTREAL , July 4, 2017 /CNW/ - Multiple myeloma, commonly referred to as myeloma, is an incurable cancer of the plasma cells found in the bone marrow. (newswire.ca)
  • Myeloma Canada is a non-profit, charitable organization created by, and for people living with multiple myeloma, a relatively unknown cancer of the plasma cells. (newswire.ca)
  • When plasma cells become cancerous and multiply, they are known as myeloma cells. (novartis.com)
  • Multiple myeloma is also known as myeloma or plasma cell myeloma. (medicalnewstoday.com)
  • Together, these biomarkers and the CRAB criteria are known as myeloma-defining events (MDEs). (wikipedia.org)
  • In addition, recent advances in technology and the mapping of the human genome have enabled scientists to discover that abnormalities in the expression, or levels, of some specific genes are associated with the risk for early relapse of multiple myeloma. (healthcentral.com)
  • The identification of genes that, when abnormally expressed, are associated with risk for relapse has led to the development of a sophisticated test that provides a gene expression profile of a person's myeloma. (healthcentral.com)
  • Although researchers have made significant progress in the treatment of myeloma over the past decade, most patients will eventually relapse, meaning new therapies are in demand. (bms.com)
  • Multiple myeloma (MM) is a hematological malignancy characterized by a high tendency to relapse and to become drug resistant. (frontiersin.org)
  • However, myeloma is characterized by cycles of disease control and relapse. (newswire.ca)
  • Phase Ib study of isatuximab and carfilzomib in relapse and refractory multiple myeloma. (nature.com)
  • People with solitary plasmacytoma have a higher risk for multiple myeloma, so you'll need regular checkups. (webmd.com)
  • Multiple myeloma is defined as clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary plasmacytoma, and one or more myeloma-defining events and biomarkers of malignancy. (medscape.com)
  • People with a history of a solitary plasmacytoma of the bone are at greater risk for developing multiple myeloma. (cancer.net)
  • Most doctors believe that plasmacytoma is simply an early, isolated form of multiple myeloma. (aaos.org)
  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. (medscape.com)
  • The International Myeloma Working Group (IMWG) was formed by the IMF to encourage dialog and collaboration among the world's leading myeloma experts. (myeloma.org)
  • NEW YORK (GenomeWeb) - The Multiple Myeloma Research Foundation (MMRF) and the University of Michigan announced today that they have partnered to provide multiple myeloma patients with access to their genomic information to help guide their treatments. (genomeweb.com)
  • 1 Recent improved understanding of the pathogenesis of myeloma has led to the development of new treatments. (bmj.com)
  • In addition, some of the treatments used to treat myeloma can damage the kidneys. (news-medical.net)
  • The MMRF relentlessly pursues innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. (volunteermatch.org)
  • We advocate to insure an increase in accessibility to high-quality diagnostics and treatments, for funding of myeloma-related research, and to end insurance coverage disparities for treatment. (myeloma.org)
  • Multiple myeloma clinical trials provide patients with exciting opportunities to be among the first to receive and benefit from promising new treatments before those options are widely available in other settings. (moffitt.org)
  • There are actually no treatments to cure multiple myeloma. (newsmax.com)
  • However, treatments are available that can help in reducing the symptoms associated with multiple myeloma. (newsmax.com)
  • If patients are suffering from symptoms associated with multiple myeloma, treatments can help. (newsmax.com)
  • One of the treatments useful for multiple myeloma patients is radiotherapy. (newsmax.com)
  • Some other treatments can be used to reduce symptoms associated with multiple myeloma. (newsmax.com)
  • Data from patients with multiple myeloma, who reported starting treatments within the last 5 years. (patientslikeme.com)
  • NEW ORLEANS -- Results of a cost analysis that compared multiple myeloma treatments found that treatment with bortezomib (Velcade) was associated with less out-of-pocket expenses than was treatment with the oral medications lenalidomide (Revlimid) and thalidomide (Thalomid). (medpagetoday.com)
  • Although there's still no cure for myeloma, various treatments are bringing about lengthy remissions, and people who were once given two to three years to live are successfully managing their condition for five to seven years, with some living a decade or longer. (harvard.edu)
  • The mission of the Multiple Myeloma Research Consortium (MMRC) is to champion collaboration with and integration across academia and industry and to focus on speed and innovation to bring the most promising multiple myeloma treatments to patients faster. (wikipedia.org)
  • We will continue to advocate, engage, support research and raise our voices for Canadians living with multiple myeloma to ensure fair and enhanced access to approved treatments in our near-future. (newswire.ca)
  • If you have multiple myeloma , cancerous plasma cells divide and grow inside your bone marrow. (webmd.com)
  • The rapid reproduction of malignant, or cancerous, myeloma cells eventually outweighs the production of healthy cells in the bone marrow. (healthline.com)
  • The resulting cancerous myeloma cells don't have a normal life cycle. (healthline.com)
  • More and more studies are showing that the gene expression profile of a cancerous tumor can help personalize treatment, and this test is the first one to be developed for multiple myeloma. (healthcentral.com)
  • In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. (mayoclinic.org)
  • A cancerous or malignant plasma cell is called a myeloma cell. (myeloma.org)
  • One of the leading theories on the cause of multiple myeloma is that the cancerous growth of plasma cells is triggered by a DNA mutation. (thirdage.com)
  • Myeloma develops when plasma cells undergo a cancerous change and turn into myeloma cells. (drugs.com)
  • Patients must have completed a stem cell transplant regimen for newly diagnosed multiple myeloma (MM) consisting of (at least) induction chemotherapy and single or tandem autologous stem cell transplant (ASCT) within eight months of study enrollment. (clinicaltrials.gov)
  • To stratify patients with newly diagnosed multiple myeloma, "traditionally, we have used the International Staging System, which is predicated on serum albumin and beta-2 microglobulin," Dr Anderson continued. (medscape.com)
  • More than 30 years after its introduction, autologous stem cell transplantation (ASCT) remains the standard of care for young patients with newly diagnosed multiple myeloma. (nature.com)
  • Amrita Krishnan, MD, FACP, elucidates various combination treatment approaches making use of daratumumab in the frontline setting for patients with newly diagnosed multiple myeloma. (ajmc.com)
  • The researchers were able to show that the NF-kappaB pathway was activated in most of the tumor samples examined from 451 patients with newly diagnosed multiple myeloma. (nih.gov)
  • In most cases of multiple myeloma, the malignant plasma cells all make an identical Ig. (encyclopedia.com)
  • In the early stages of multiple myeloma, you might not have symptoms, or they might be very mild. (webmd.com)
  • During the early stages of multiple myeloma, no symptoms may be apparent. (reference.com)
  • Clinical trials are used for all types and stages of multiple myeloma. (cancer.net)
  • About 70% of individuals with multiple myeloma have soft spots or lesions in their bones. (encyclopedia.com)
  • These chromosome abnormalities may be an explanation for the wide variation in response to treatment among individuals with multiple myeloma. (healthcentral.com)
  • For individuals with multiple myeloma-those newly diagnosed to survivors of many years-and their family members and friends…all are welcome! (parknicollet.com)
  • Multiple myeloma is characterized by abnormalities in plasma cells, a type of white blood cell. (medlineplus.gov)
  • Somatic mutations, which are genetic changes that are not inherited but occur during an individual's lifetime in certain cells (in this case the plasma cells), have been identified in people with multiple myeloma. (medlineplus.gov)
  • Mutations in these genes may interfere with proper control (regulation) of cell growth and division (proliferation), resulting in the excessive proliferation of plasma cells that characterizes multiple myeloma. (medlineplus.gov)
  • Multiple myeloma is a disease in which malignant plasma cells spread through the bone marrow and hard outer portions of the large bones of the body. (encyclopedia.com)
  • Whereas normal bone marrow contains less than 5% plasma cells, bone marrow of an individual with multiple myeloma contains over 10% plasma cells. (encyclopedia.com)
  • Multiple myeloma leads to the production of too many plasma cells inside the bone marrow. (medicalnewstoday.com)
  • Normally, less than 5 percent of bone marrow consists of plasma cells, but in multiple myeloma, plasma cells can make up more than 10 percent of the marrow. (medicalnewstoday.com)
  • These cells are known as malignant plasma cells, or myeloma cells. (oncolink.org)
  • Multiple myeloma (MM) is a malignancy of plasma cells characterized by growth in the bone marrow (BM) environment and the development of lytic lesions in the skeleton. (springer.com)
  • This test can tell the difference between normal plasma cells and abnormal plasma cells (myeloma cells). (nccn.org)
  • In multiple myeloma, blood cells known as plasma cells start to grow out of control. (healthcentral.com)
  • Genetic and chromosomal tests - Specialized tests can reveal genetic or chromosomal abnormalities of the plasma cells that are usually associated with multiple myeloma. (moffitt.org)
  • As their number escalates, myeloma cells displace healthy ones within the bone marrow in a process that, in turn, suppresses the growth of normal plasma cells that help fight infection. (nurse.com)
  • A person must have >10 % clonal plasma cells and any MDE to be diagnosed with myeloma. (wikipedia.org)
  • Multiple myeloma (MM) is a clonal proliferation of malignant plasma cells. (unboundmedicine.com)
  • Plasma cells undergo multiple chromosomal mutations to progress to MM. (unboundmedicine.com)
  • Multiple myeloma occurs when plasma cells become abnormal and begin to divide and reproduce in an uncontrolled way. (patientslikeme.com)
  • Researchers are not yet sure of what causes the abnormal replication of plasma cells found in multiple myeloma patients. (thirdage.com)
  • In multiple myeloma, a type of white blood cell known as plasma cells multiply too rapidly in the bone marrow. (healthgrades.com)
  • In patients with multiple myeloma, the malignant plasma cells produce only one type of intact (whole) immunoglobulin in large amounts. (labtestsonline.org.uk)
  • Normally, the body makes as many plasma cells as it needs but when a person has multiple myeloma, too many plasma cells are made. (cancervic.org.au)
  • Multiple myeloma cells come from changed plasma cells. (aaos.org)
  • The 5-year survival rate for multiple myeloma is 49 percent. (medicalnewstoday.com)
  • In fact, a well-recognized feature of MM is the presence of an intimate relationship between PC and bone marrow microenvironment where PC are hosted in special niches and receive multiple signals that maintain their long survival and exert a protective effect on drug-induced apoptosis. (hindawi.com)
  • The IMF's guide through the myeloma journey, from diagnosis to long-term survival. (myeloma.org)
  • Mcl-1 regulates a number of processes that promote cell survival and has been implicated in resistance to anti-myeloma drugs that were initially effective. (eurekalert.org)
  • What is the multiple myeloma survival rate? (reference.com)
  • A study shows prescription drug coverage leads to better survival among Medicare beneficiaries with multiple myeloma. (cancernetwork.com)
  • Relapsed or refractory multiple myeloma patients experience high response rates, overall survival with bortezomib-based therapy. (cancernetwork.com)
  • In vitro sclerostin did not affect growth, proliferation, or survival of multiple myeloma cells. (medpagetoday.com)
  • They also studied the effect of sclerostin on growth and survival of multiple myeloma cells in vitro. (medpagetoday.com)
  • Exogenous recombinant sclerostin did not affect multiple myeloma cell viability, survival, or proliferation," Eda reported. (medpagetoday.com)
  • Despite its confirmed significant impact on event-free survival (EFS), multiple trials failed to depict significant impact on overall survival (OS) 9 . (nature.com)
  • Data predicts that there will be over a 57% increase in the number of multiple myeloma patients by 2030 as a result of achieving longer survival for these patients and the population aging. (prnewswire.com)
  • Multiple myeloma (MM) is a complex and heterogeneous disease [ 1 , 2 , 3 ], with variable survival. (intechopen.com)
  • Despite recent therapeutic advances, which have doubled the median survival time, myeloma continues to be a mostly incurable disease. (jci.org)
  • Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. (nature.com)
  • A growth factor , called interleukin-6, promotes uncontrolled growth of these myeloma cells in the bone marrow and prevents their natural death. (encyclopedia.com)
  • The Igs from myeloma cells are nonfunctional and are called paraproteins. (encyclopedia.com)
  • In addition, malignant myeloma cells produce factors that affect cells called osteoclasts. (encyclopedia.com)
  • Myeloma cells have more chromosomes than normal. (webmd.com)
  • These myeloma cells have fewer chromosomes than normal. (webmd.com)
  • Low immunity or recurrent infections - The spread of myeloma cells throughout the bone marrow may also cause depletion of the white blood cells, lowering immunity and leaving a patient vulnerable to infections. (news-medical.net)
  • Kidney damage - Myeloma cells produce an abnormal protein that can damage the kidneys as they pass from the blood and into the urine. (news-medical.net)
  • When a buildup of myeloma cells occurs, it can overwhelm the production of healthy cells, causing damage to the bone as well as low blood counts. (novartis.com)
  • When myeloma cells collect in several sites, it is called multiple myeloma. (novartis.com)
  • Some patients also become refractory, which means they stop responding to treatment and still have myeloma cells in their bone marrow. (novartis.com)
  • Because your bone marrow makes blood, multiple myeloma can affect how many healthy blood cells you have. (webmd.com)
  • There aren't that many myeloma cells in the body. (webmd.com)
  • There are more myeloma cells in the body than in stage I. (webmd.com)
  • Shortages of red blood cells, white blood cells, and blood platelets are common in multiple myeloma and might lead to other symptoms. (cancer.org)
  • These are called myeloma cells. (medicalnewstoday.com)
  • The abnormal myeloma cells start in the bone marrow of the spine. (medicalnewstoday.com)
  • In the case of MILs, the T cells targeted for harvesting are myeloma specific. (medscape.com)
  • Specifically, in long-term follow-up of a clinical study of MILs initiated in 2007, myeloma antigen-specific T cells were recovered from the bone marrow up to 7 years after infusion. (medscape.com)
  • Conversely, bone marrow biopsies conducted in those who did not achieve CR demonstrated loss of myeloma antigen-specific T cells in most cases. (medscape.com)
  • Research on mice also suggests that curcumin may slow the growth of multiple myeloma cells. (healthline.com)
  • A pathologist will view the samples under a microscope to look for myeloma cells. (nccn.org)
  • Flow cytometry This is a test that measures the amount of myeloma cells in the bone marrow. (nccn.org)
  • It is used to measure the number of myeloma cells in the bone marrow. (nccn.org)
  • This type of test is used to look for abnormal changes in the chromosomes of the myeloma cells. (nccn.org)
  • Myeloma cells can also be examined with a test called FISH. (nccn.org)
  • The newest testing, called gene expression , looks for certain genes that may be turned on or turned off in myeloma cells. (nccn.org)
  • Plasma cell proliferation This test shows what percentage of the myeloma cells are dividing. (nccn.org)
  • This is caused by stimulation of bone eating cells (called osteoclasts) by cytokines released from myeloma cells. (moffitt.org)
  • This can be caused by myeloma cells leaving little space for healthy bone marrow cells responsible for production of red blood cells or by myeloma cells releasing cytokines that suppress these cells. (moffitt.org)
  • In addition to these "CRAB" problems, myeloma cells can weaken the immune system and increase the risk for infections. (moffitt.org)
  • In addition, the unique mutations in antibody genes of myeloma cells are identified. (moffitt.org)
  • In the bone marrow, myeloma cells crowd out healthy blood cells, leading to fatigue and an inability to fight infections. (mayoclinic.org)
  • While several drugs are effective against multiple myeloma, including the proteasome inhibitor bortezomib, multiple myeloma cells are often able to survive by increasing the production of a protein known as Mcl-1. (eurekalert.org)
  • This research builds on our previous studies that showed exposing multiple myeloma and leukemia cells to Chk1 inhibitors activated a protective response through the Ras/MEK/ERK signaling pathway," says Pei, instructor in the Department of Internal Medicine at the VCU School of Medicine. (eurekalert.org)
  • In laboratory experiments, the scientists enforced overexpression of Mcl-1 in human multiple myeloma cells. (eurekalert.org)
  • Some myeloma cells are too immature to be caught by the drugs and thus hide underground only to reemerge later," says Keith Stewart, M.B., Ch.B., Dean for Research at Mayo Clinic in Arizona and contributor to the study. (redorbit.com)
  • As myeloma cells divide and increase in number, they can affect the body in various ways. (mskcc.org)
  • Although sclerostin stimulates the molecular cascade that leads to osteoclastogenesis, the protein has no impact on multiple myeloma cells, Eda said at this poster presentation during the annual meeting of the American Society of Hematology. (medpagetoday.com)
  • Myeloma cells secrete chemicals that stimulate osteoclasts (which are cells that break down bone, removing calcium). (drugs.com)
  • Myeloma cells also produce an abnormal type of immunoglobulin that can be detected in the blood. (drugs.com)
  • Myeloma cells display a promising target for immunotherapy called B-cell maturation antigen (BCMA), which is found in 60 to 70 percent of multiple myeloma patients. (bms.com)
  • BCMA is also used in another immunotherapy approach for myeloma called chimeric antigen receptor T-cells (CAR T) therapy. (bms.com)
  • An increase in the number of multiple myeloma cells crowds out the normal cells and destroys them. (rxlist.com)
  • The research team initially analyzed high-throughput screening assays of 7,500 genes in multiple myeloma cells to identify effectors of drug response, and then studied bone marrow biopsies from patients to further understand their results. (medindia.net)
  • Anti-nausea drug thalidomide when combined with turmeric can effectively kill multiple myeloma cells, say researchers. (medindia.net)
  • The research team's discovery began with the observation that the NF-kappaB pathway was activated in a majority of the multiple myeloma research cells they tested. (nih.gov)
  • Using an inhibitor of a key enzyme, named IkappaB kinase beta, needed to activate this pathway, the researchers demonstrated that these myeloma cells either died or stopped dividing when the NF-kappaB pathway was disrupted. (nih.gov)
  • To identify the specific genes that might be driving NF-kappaB activation in multiple myeloma, the researchers studied genes known to regulate the NF-kappaB pathway in normal cells, focusing on those with abnormally high or low expression levels in samples from patients with multiple myeloma. (nih.gov)
  • The Washington University Center for Multiple Myeloma Nanotherapy (WU CMMN) will address overarching questions in bone malignancies, with a focus on multiple myeloma (MM). MM is a hematopoietic disease caused by terminally differentiated malignant plasma B-cells. (cancer.gov)
  • To diagnose multiple myeloma, your doctor will do a combination of tests. (webmd.com)
  • Professor Chris Bunce, research director at Leukemia & Lymphoma Research , says this research offers more evidence that the risk of myeloma can be inherited. (medicalnewstoday.com)
  • The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. (lls.org)
  • Multiple myeloma often times originates in the bone marrow and is similar to diseases such as leukemia and lymphoma. (reference.com)
  • a U.S. specialty pharmaceutical company and Clinigen Group plc (AIM: CLIN, 'Clinigen') , the global pharmaceutical and services company, announce a new publication in Leukemia & Lymphoma , with study results showing that amifostine decreases gastro-intestinal (GI) toxicity in patients who receive treatment for their multiple myeloma. (prnewswire.com)
  • Lenalidomide, Bortezomib, and Dexamethasone With Transplantation for Myeloma. (medicinenet.com)
  • Panobinostat used in combination with bortezomib in relapsed multiple myeloma was shown to be superior to bortezomib alone, he explained. (medscape.com)
  • Eda said that the proteasome inhibitor bortezomib (Velcade) had properties that block the effects of sclerostin and that action may be one of the reasons that bortezomib therapy has been a mainstay of treatment for individuals diagnosed with multiple myeloma. (medpagetoday.com)
  • One year after diagnosis with multiple myeloma, the adjusted out-of-pocket costs for a patient treated with bortezomib was about $3,504, Pinsky reported. (medpagetoday.com)
  • These data demonstrate that increased sclerostin levels in multiple myeloma patients inhibit osteoblastogenesis and stimulate osteoclastogenesis," he suggested. (medpagetoday.com)
  • NEW YORK (GenomeWeb) - Researchers from Erasmus MC University Medical Center and Radboud University Medical Center in The Netherlands have developed a mass spec-based test for measuring M protein levels in multiple myeloma patients. (genomeweb.com)
  • Previous studies indicated that around four percent of multiple myeloma patients may have mutations in this gene, and a recent report on a single multiple myeloma patient treated with drugs targeting BRAF showed promising results. (eurekalert.org)
  • Myeloma bone disease is due to the overexpression of receptor activator for nuclear factor κ B ligand ( RANKL ) by bone marrow stroma . (wikipedia.org)
  • Throughout the multiple myeloma journey, a treatment team works with the patient to introduce different therapy combinations to address treatment resistance and/or disease progression. (novartis.com)
  • Myeloma today: Disease definitions and treatment advances. (medscape.com)
  • Multiple myeloma also causes kidney disease in some people. (healthline.com)
  • The researchers say that this latest discovery takes the number of total genetic variants linked to myeloma to seven, and may help lead to the discovery of genetic causes of the disease. (medicalnewstoday.com)
  • Diagnosing multiple myeloma can be tricky for your doctor, as the symptoms of this disease tend to show up in the late, rather than early, stages. (wikihow.com)
  • Multiple myeloma is a pretty rare disease-the average American's risk of getting at some point is just one in 132. (healthcentral.com)
  • The disease has no cure, but multiple myeloma treatment improves every year. (healthcentral.com)
  • But multiple myeloma is genetic in the sense that the genes contained in your DNA play a pretty big role in raising your risk of the disease. (healthcentral.com)
  • For people with multiple myeloma who require treatment, a number of options are available to help control the disease. (mayoclinic.org)
  • Treatment for multiple myeloma is focused on decreasing the clonal plasma cell population and consequently decrease the symptoms of disease. (wikipedia.org)
  • According to WebMD, risk factors that can make people more vulnerable to multiple myeloma include being male, over 65 years of age, African-American, and having family members who have been afflicted by the disease. (reference.com)
  • Multiple myeloma is a disease that can often be treated successfully, and many patients live long and productive lives after being diagnosed. (myeloma.org)
  • First-degree relatives of people with multiple myeloma have a 2- to 4-fold increased risk of developing the disease. (cancer.net)
  • Recent research into multiple myeloma has been very successful and oncologists say there are many promising new therapies today that treat the disease more effectively than ever before. (healthgrades.com)
  • Multiple myeloma symptoms can be vague and often don't occur until later in the disease. (healthgrades.com)
  • One of the characteristic findings in multiple myeloma is osteolytic bone disease. (medpagetoday.com)
  • Taken together, sclerostin may be a good target to inhibit myeloma bone disease and help restore normal bone homeostasis. (medpagetoday.com)
  • Early in the disease process, multiple myeloma may not cause any symptoms, and even after diagnosis, treatment may not be needed immediately. (drugs.com)
  • Multiple myeloma is a complex disease that places a significant burden on patients or their caregivers," said Brett Pinsky, MPH, a senior researcher at i3 Innovus, Eden Prairie, Minn., in a poster presentation at the American Society of Hematology meeting. (medpagetoday.com)
  • In myeloma, this is always the case due to the nature of the disease. (cancer.net)
  • Concomitant malignancies or previous malignancies (other than multiple myeloma) with less than a 2-year disease-free interval at the time of first dose of study drug. (pfizer.com)
  • It was designed to rapidly accelerate progress made against multiple myeloma by significantly improving the understanding of the biology of the disease. (wikipedia.org)
  • To do so, Myeloma Canada conducts frequent surveys amongst patients and caregivers in Canada to evaluate disease impact on quality of life, patient needs, treatment expectations and impact of new therapies. (newswire.ca)
  • Cite this: Cellular Immunotherapy for Multiple Myeloma Advancing Rapidly - Medscape - Jan 30, 2017. (medscape.com)
  • In this paper we discuss how the interaction between the malignant plasma cell and the BM microenvironment allowed myeloma progression through cell homing and the new concept of premetastatic niche. (hindawi.com)
  • You may also be susceptible to contracting infections and illnesses due to the multiple myeloma. (wikihow.com)
  • Multiple myeloma is discovered through routine blood screening when patients are being evaluated for other problems such as frequent infections. (rxlist.com)
  • Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. (nih.gov)
  • Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma. (nih.gov)
  • Patients in the United States and Canada who had received at least one previous therapy for multiple myeloma but who required additional treatment were randomly assigned to receive either 25 mg of lenalidomide or placebo on days 1 to 21 of a 28-day cycle. (nih.gov)
  • Lenalidomide plus dexamethasone is superior to placebo plus dexamethasone in patients with relapsed or refractory multiple myeloma. (nih.gov)
  • A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. (nature.com)
  • Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. (nature.com)
  • In some patients, large amounts of myeloma protein can cause the blood to "thicken. (cancer.org)
  • During lab tests, indicators of multiple myeloma are anemia, protein in urine, elevated creatine, and high blood calcium. (reference.com)
  • A small study found elevated plasma levels of sclerostin, an osteocyte-secreted protein that inhibits osteoblasts and stimulates osteoclastogenesis, in patients with multiple myeloma compared with those who have other cancers or normal volunteers. (medpagetoday.com)
  • SAN DIEGO -- High levels of the osteocyte-secreted protein sclerostin are found in patients with multiple myeloma and that finding could give scientists a therapeutic target, researchers said here. (medpagetoday.com)
  • The type of myeloma a patient has is often referred to by the type of M protein or paraprotein produced, whether an intact immunoglobulin or light chain. (labtestsonline.org.uk)
  • If a patient has elevated protein levels, several tests are conducted, and their combined results are interpreted to make a myeloma diagnosis. (mdanderson.org)
  • A bone marrow biopsy can help diagnose this type of myeloma. (webmd.com)
  • Based off of the MRI and a bone marrow biopsy collected by the doctors who repaired my back, Dr. York was able to quickly diagnose my multiple myeloma. (healthgrades.com)
  • Indeed, MM PC are not able to grow in a medium without a stromal support and even PC from patients affected by refractory myeloma show drug sensitivity when cultured in vitro [ 9 ]. (hindawi.com)
  • A study shows comprehensive sequencing approach can identify treatment options in patients with relapsed and/or refractory myeloma. (cancernetwork.com)
  • Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. (medscape.com)
  • Although the mutations that cause myeloma are acquired and not inherited, family history is a known risk factor for multiple myeloma. (cancer.net)
  • About one-third of people affected by multiple myeloma have no symptoms. (mskcc.org)
  • Noopur Raje, MD, assistant professor of medicine and director of the Center for Multiple Myeloma at Massachusetts General Hospital/Harvard Medical School said, however, that cost was often not a major factor in selection of treatment regimens for multiple myeloma. (medpagetoday.com)
  • Multiple myeloma is considered treatable, but generally incurable. (wikipedia.org)
  • Multiple myeloma remains incurable, despite the significant improvement in treatment over the past 10 years. (prnewswire.com)
  • Multiple Myeloma caught public attention when model turned actress Lisa Ray, who worked in Deepa Mehta's 'Water' , declared that she had the incurable Multiple Myeloma. (medindia.net)
  • Retrieved on June 22, 2021 from https://www.news-medical.net/health/Multiple-Myeloma-Epidemiology.aspx. (news-medical.net)
  • Multiple myeloma is a heterogeneous hematological malignancy in which epidemiology plays an increasingly important role. (intechopen.com)
  • Anemia - Either multiple myeloma itself or treatment for the condition may lower the red blood cell count and cause anemia which may lead to weakness, fatigue and shortness of breath. (news-medical.net)
  • Bleeding and bruising tendencies - Blood platelets, which are involved in the blood clotting process are also made in the bone marrow and multiple myeloma can lead to a depleted platelet count and an increased tendency to bruise and bleed. (news-medical.net)
  • Multiple myeloma can lead to too much calcium in your blood. (webmd.com)
  • Multiple myeloma and high levels of calcium can hurt your kidneys and make it harder for them to filter your blood. (webmd.com)
  • Doctors can tell what stage the multiple myeloma is in by looking at X-rays of your bones and testing your blood, pee, and bone marrow. (webmd.com)
  • High calcium levels in the blood can also indicate myeloma, as calcium from the bones dissolves into the bloodstream. (medicalnewstoday.com)
  • Anemia, or a low red blood cell count, is a common complication in people with multiple myeloma. (healthline.com)
  • Doctors know that myeloma begins with one abnormal plasma cell in your bone marrow - the soft, blood-producing tissue that fills in the center of most of your bones. (mayoclinic.org)
  • Multiple myeloma can be treated using chemotherapy and other treatment options after identification through blood tests and other diagnostic methods. (newsmax.com)
  • In the research, Eda and colleagues measured sclerostin concentration in the blood plasma of 20 multiple myeloma patients. (medpagetoday.com)
  • However, in some cases, your doctor might suspect multiple myeloma based on a blood or urine test taken for another reason. (drugs.com)
  • Nicotine can damage blood vessels and make it more difficult to manage your multiple myeloma. (drugs.com)
  • People with multiple myeloma should have regular blood tests to confirm their counts are in a safe range. (livestrong.com)
  • The MMRC also includes a shared tissue bank of annotated tissue and peripheral blood samples from multiple myeloma patients. (wikipedia.org)
  • The most common way to diagnose myeloma before symptoms appear is through routine blood work. (mdanderson.org)